DNA editing method, cell production method using same, and DNA editing vector and DNA editing kit for use in said methods

The DNA editing method employs site-specific nucleases and autonomously replicating sequences to achieve precise and efficient insertion and removal of nucleotide sequences, addressing inefficiencies and regulatory issues in existing techniques by ensuring cells are free from unwanted genetic material.

WO2024237339A1PCT designated stage expired Publication Date: 2024-11-21MAZDA MOTOR CORP +2
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/018374
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-18
Filing Date
2024-05-17
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current DNA insertion methods are inefficient and often leave foreign genes in genetically modified cells, making them less useful due to regulatory restrictions, and existing techniques for removing these genes are cumbersome and not highly efficient.

Method used

A DNA editing method using a site-specific nuclease system, such as TALEN or CRISPR-Cas, with a vector structure that allows for accurate and efficient insertion or removal of desired nucleotide sequences by cleaving genomic DNA and using autonomously replicating sequences like CEN/ARS to facilitate vector shedding post-insertion.

Benefits of technology

Enables the precise insertion of desired nucleotide sequences into target sites in cells and their subsequent removal, resulting in genomic DNA-edited cells free from foreign genes with high efficiency and accuracy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024018374_21112024_PF_FP_ABST
    Figure JP2024018374_21112024_PF_FP_ABST
Patent Text Reader

Abstract

Provided is a DNA editing method in which a desired nucleotide sequence is inserted into a target site in target DNA in a cell, or the target site is removed. The method includes an introduction step for introducing a vector and a site-specific nuclease system into the cell so as to come into contact with the target DNA, wherein the vector includes a first promoter P1 and a structure (1): 5'-M1-Hv1-D-Hv2-M2-3' wherein M1 represents a 5'-side fragment of a nucleotide sequence encoding a selection marker gene and is operably linked to P1, Hv1 represents a nucleotide sequence homologous to a first nucleotide sequence Ht1 located on the 5'-side of the target site in the target DNA, D represents the desired nucleotide sequence and may be absent, Hv2 represent a nucleotide sequence homologous to a second nucleotide sequence Ht2 located on the 3'-side of the target site in the target DNA, and M2 represents a remaining 3'-side fragment of the nucleotide sequence encoding the selection marker gene. The method also includes: a cleavage step in which a fragment represented by a structure (2): 5'-Hv1-D-Hv2-3' and a fragment represented by a structure (3): 5'-M2-P1-M1-3' are generated from the vector using the site-specific nuclease system, and the target site or a portion surrounding the target site is cleaved in the target DNA; an editing step in which the target DNA and the structure (2) are bound to each other depending on the homology between Ht1 and Hv1 and are bound to each other depending on the homology between Ht2 and Hv2, so that the desired nucleotide sequence D is inserted into the target site or the target site is removed; and a selection step in which a 3'-end of M1 and a 5'-end of M2 are bound to each other in the fragment represented by the structure (3) to produce a selection vector containing a selection marker gene that is operably linked to P1 and is capable of functioning.
Need to check novelty before this filing date? Find Prior Art

Description

DNA editing method, cell production method using the same, and DNA editing vector and DNA editing kit for use in these methods

[0001] The present invention relates to a DNA editing method, a cell production method using the same, and a DNA editing vector and a DNA editing kit for use in these methods.

[0002] In recent years, there has been active development of DNA editing technologies for useful organisms, and methods have been developed that use site-specific nuclease systems, such as the CRISPR-Cas system, a system in which a nuclease is fused to a TAL effector (TALE) (TALEN), or a system in which a nuclease is fused to a zinc finger (ZF), to specifically cleave a target site in a target DNA within a cell or its vicinity, thereby editing the nucleotide sequence of the target site.

[0003] These DNA editing techniques mainly employ a method in which a nucleotide sequence encoding a selectable marker gene for confirming the editing is also introduced into cells. For example, Non-Patent Document 1 (Yan et al., Molecular Therapy: Nucleic Acids, Vol. 19 March, 2020, pp. 775-789) describes a method in which a vector containing a CRISPR-Cas system and an inactive puromycin resistance gene is introduced into cells, and the inactive puromycin resistance gene is activated by the cleavage activity of the CRISPR-Cas system, thereby selecting cells in which the CRISPR-Cas system is expressed. Furthermore, for example, Non-Patent Document 2 (Mashiko et al., Develop. Growth Differ. 2014, 56, pp. 122-129) describes a method in which a nucleotide sequence encoding the fluorescent protein GFP is divided into two halves, and a vector having a sequence to be cleaved by the CRISPR-Cas system sandwiched between the two halves is introduced into cells, and cells in which the CRISPR-Cas system is expressed produce fluorescence and are selected.

[0004] However, no technology has yet been developed for using these methods in DNA insertion methods for inserting a nucleotide sequence into target DNA. Furthermore, DNA insertion methods require precise orientation and positioning of the nucleotide sequence to be inserted. Known DNA insertion methods include, for example, adding sequences homologous to 500 to 2000 bases of the nucleotide sequence at both ends of a desired nucleotide sequence, and then replacing the desired nucleotide sequence with the target sequence by homologous recombination (HR), or inserting the desired nucleotide sequence into the target sequence. However, these methods have drawbacks, such as the long vectors used making them difficult to prepare, low homologous recombination efficiency, and limited applicability to certain cells. Another known DNA insertion method aimed at overcoming these drawbacks is microhomology-mediated end joining (MMEJ), which utilizes a short homologous sequence of about 20 bases. For example, Patent Document 1 (WO 2015 / 068785) describes a method in which a site-specific nuclease system and a vector containing a desired nucleotide sequence are introduced into a cell, and the desired nucleotide sequence is inserted into a predetermined site.

[0005] However, in conventional DNA insertion techniques, it is necessary to also introduce into cells a sequence encoding the above-mentioned selectable marker gene for confirming the insertion, and therefore foreign genes other than the target nucleotide sequence remain in the resulting cells. Cells containing such foreign genes are subject to various limitations on their use as genetically modified cells, making them less useful.

[0006] As a method for removing foreign genes other than the target nucleotide sequence, for example, Non-Patent Document 3 (Kurita et al., Scientific reports, 2022, 12:2480, https: / / doi.org / 10.1038 / s41598-022-06495-y) describes a method in which an all-in-one PtTALEN-ARS vector encoding a nucleotide sequence encoding a CEN / ARS and a TALEN is used, the TALEN is introduced into cells to achieve the desired cleavage, and then the cells are cultured to eliminate the all-in-one PtTALEN-ARS vector from the cells.

[0007] International Publication No. 2015 / 068785

[0008] Yan et al. , Molecular Therapy: Nucleic Acids, Vol. 19 March, 2020, p. 775-789 Mashiko et al. , Develop. Growth Differ. 2014, 56, p. 122-129Kurita et al. , Scientific reports, 2022, 12:2480, https: / / doi. org / 10.1038 / s41598-022-06495-y

[0009] The present invention has been made in consideration of the problems associated with the above-mentioned conventional technologies, and aims to provide a DNA editing method that can accurately and efficiently insert a desired nucleotide sequence into a target site of target DNA in a cell using a vector, or remove the target site, a cell production method using the same, and a DNA editing vector and DNA editing kit for use in these methods.

[0010] The present inventors conducted extensive research to achieve the above-mentioned objective. First, they attempted to insert an endogenous promoter (ProLDSP) into a target site immediately before the start codon of a target gene (LPAT1) in genomic DNA. The DNA to be inserted was a nucleotide fragment (knock-in fragment) in which sequences homologous to the sequence immediately before the start codon of LPAT1 (first nucleotide sequence) and the sequence after the start codon (second nucleotide sequence) were added to both ends of the nucleotide sequence of ProLDSP. Furthermore, a site-specific nuclease, TALEN, was designed to cleave the target site or its surroundings. It was believed that by introducing these into cells, the genomic DNA was cleaved by the TALEN, and the ends of the nucleotide fragment bound to the first and second nucleotide sequences of the genomic DNA in a homologous manner, thereby inserting ProLDSP into the target site and overexpressing LPAT1, a gene involved in membrane lipid synthesis. Furthermore, by introducing and expressing the expression vector described in Non-Patent Document 3 (all-in-one PtTALEN-ARS vector) containing CEN / ARS as an autonomous replication sequence as a TALEN, it is possible to remove the DNA by culture after insertion, and it was therefore thought possible to obtain DNA-edited cells that do not contain any foreign genes other than ProLDSP (Figure 4).

[0011] However, using the above method, it was difficult to obtain the desired DNA-edited cells into which the nucleotide fragment was inserted. Therefore, the inventors conducted further studies and found that one of the reasons for this was that the method for selecting cells into which the nucleotide fragment and a site-specific nuclease expression vector (all-in-one PtTALEN-ARS vector) were simultaneously introduced relied solely on the selection marker derived from the site-specific nuclease expression vector, resulting in low efficiency in obtaining cells into which both were introduced. Therefore, they constructed a new method. Specifically, in the above method, the nucleotide fragment to be introduced was designed on a vector containing a selection marker gene (a selection marker gene separate from the site-specific nuclease expression vector), and the selection marker gene was divided into a 5' fragment and a 3' fragment, with the nucleotide fragment sandwiched between them and designed to be excised by the site-specific nuclease. By introducing this and a site-specific nuclease expression vector into cells, the genomic DNA is cleaved by the site-specific nuclease, and the nucleotide fragment is also excised, and both ends of the nucleotide fragment bind to the first nucleotide sequence and the second nucleotide sequence of the genomic DNA, respectively, depending on their homology. At the same time, in cells where the cleavage and insertion have occurred, the 5'- and 3'-fragments of the remaining vector fragment from which the nucleotide fragment has been excised bind, causing the selection marker gene to function. Therefore, by selecting according to the selection marker gene, it is possible to efficiently obtain the cells, i.e., cells into which a vector containing the nucleotide fragment and a site-specific nuclease expression vector have been simultaneously introduced, with high efficiency. Furthermore, it is difficult for cells to grow with each of the introduced vectors alone. Furthermore, if the introduced vector contains CEN / ARS, the vector in which the selection marker gene has functioned contains CEN / ARS, so it can be removed by culture together with the site-specific nuclease expression vector after DNA insertion (Figures 2A and 2B).

[0012] The present inventors developed and tested various vectors based on the above-mentioned newly constructed method, and found that they were able to accurately insert the desired nucleotide fragment into the target site in cells. Furthermore, when the introduced vector contained a CEN / ARS, they were also able to successfully eliminate each vector from the cell after DNA insertion. The present inventors named this new DNA editing method the Non-Integrative Cleavage-Dependent System (NICS system). Furthermore, the vector used in this method, in which the selectable marker gene is split into a 5' fragment and a 3' fragment and the above-mentioned nucleotide fragment is sandwiched between them, is named the NICS vector. Using these, the desired nucleotide sequence can be accurately and efficiently inserted into the target site of the target DNA in the cell by the vector. Furthermore, by including a CEN / ARS in the vector, the vector can be subsequently eliminated, and genomic DNA-edited cells in which foreign genes other than the inserted nucleotide sequence have been removed can be obtained with high efficiency. Furthermore, the present inventors have also found that, conversely, by using this method to insert a nucleotide sequence of 0 bases and a target site of several bases or more, the target site can be accurately and efficiently removed from the target DNA (Figure 1B), leading to the completion of the present invention.

[0013] [1] A method for editing DNA to insert a desired nucleotide sequence into a target site of target DNA in a cell or to remove the target site, comprising an introduction step of introducing a vector and a site-specific nuclease system into a cell and contacting the vector with the target DNA, wherein the vector comprises: a first promoter P1; and a nucleotide sequence having the following structure (1): 5'-M1-Hv1-D-Hv2-M2-3' ... (1) [In (1), M1 represents a 5' fragment of a nucleotide sequence encoding a selectable marker gene and is operably linked to a first promoter P1; Hv1 represents a nucleotide sequence homologous to a first nucleotide sequence Ht1 on the 5' side of the target site of the target DNA; D represents the desired nucleotide sequence but is optional; Hv2 represents a nucleotide sequence homologous to a second nucleotide sequence Ht2 on the 3' side of the target site of the target DNA; M2 represents the remaining 3' fragment of the nucleotide sequence encoding the selectable marker gene; and adjacent sequences in M1, Hv1, D, Hv2, and M2 may partially overlap each other. and a cutting step of generating from the vector a fragment represented by the following structure (2): 5'-Hv1-D-Hv2-3' ... (2) and a fragment represented by the following structure (3): 5'-M2-P1-M1-3' ... (3) from the vector by the site-specific nuclease system, and cutting the target site or its periphery in the target DNA; an editing step of binding between the target DNA and the fragment represented by structure (2) depending on the homology between Ht1 and Hv1, and binding between Ht2 and Hv2, thereby inserting a desired nucleotide sequence D into the target site or removing the target site; and a selection step of binding between the 3' end of M1 and the 5' end of M2 in the fragment represented by structure (3) to obtain a selection vector operably linked to P1 and containing a functional selection marker gene.

[0014] [2] The DNA editing method according to [1], wherein the vector further comprises an autonomously replicating sequence CEN / ARS, the structure (3) produced in the cleavage step further comprises CEN / ARS, and the selection step is a step in which the 3' end of M1 and the 5' end of M2 in the fragment represented by structure (3) are joined to obtain a selection vector that is operably linked to P1 and contains a functional selection marker gene and CEN / ARS.

[0015] [3] The DNA editing method according to [1] or [2], wherein the length of Hv1 and the length of Hv2 are each independently 30 to 600 bases.

[0016] [4] The vector has the following structure (11) as the structure (1): 5'-M1-T1-Hv1-D-Hv2-T2-M2-3' ... (11) [In (11), T1 represents a TALEN_1 binding region comprising a first DNA-binding domain recognition sequence or its complementary sequence L1, and a second DNA-binding domain recognition sequence or its complementary sequence R1, T2 represents a TALEN_2 binding region comprising a third DNA-binding domain recognition sequence or its complementary sequence L2, and a fourth DNA-binding domain recognition sequence or its complementary sequence R2, M1, Hv1, D, Hv2, and M2 are each defined as in the structure (1), and adjacent sequences in M1, T1, Hv1, D, Hv2, T2, and M2 may partially overlap each other. and a TALEN_3 that cleaves the target site or a periphery of the target DNA. The DNA editing method of any one of [1] to [3], wherein the site-specific nuclease system comprises a TALEN comprising a DNA-binding domain and a nuclease domain: TALEN_1 comprising a first DNA-binding domain and a second DNA-binding domain, and generating the 5'-end of structure (2); TALEN_2 comprising a third DNA-binding domain and a fourth DNA-binding domain, and generating the 3'-end of structure (2); and TALEN_3 comprising a fifth DNA-binding domain that recognizes a nucleotide sequence on the 5'-side of region T3 containing the target site of the target DNA as a fifth DNA-binding domain recognition sequence or its complementary sequence L3, and a sixth DNA-binding domain that recognizes a nucleotide sequence on the 3'-side of region T3 containing the target site of the target DNA as a sixth DNA-binding domain recognition sequence or its complementary sequence R3, and cleaves the target site or a periphery of the target DNA.

[0017] [5] The vector comprises, in a structure (1), a first guide RNA recognition sequence or its complementary sequence G1, and a second guide RNA recognition sequence or its complementary sequence G2, and G1 may be between M1 and Hv1 and overlap with at least one of M1 and Hv1, and G2 may be between M2 and Hv2 and overlap with at least one of M2 and Hv2; the site-specific nuclease system is a CRISPR-Cas system comprising a Cas protein and its guide RNA, wherein: CRISPR-Cas system_1 comprises a first guide RNA, and the Cas protein generates the 5' end of structure (2); and CRISPR-Cas system_2 comprises a second guide RNA, and the Cas protein generates the 3' end of structure (2); and a CRISPR-Cas system_3, which includes a third guide RNA that recognizes a nucleotide sequence present so as to include the target site of the target DNA as a third guide RNA recognition sequence or its complementary sequence G3, and in which a Cas protein cleaves the target site or its surroundings in the target DNA. The DNA editing method according to any one of [1] to [3],

[0018] [6] The DNA editing method according to any one of [1] to [5], wherein the introduction of the site-specific nuclease system into the cell is the introduction of a nuclease system expression vector comprising: an autonomously replicating sequence CEN / ARS; a second promoter P2; and a nucleotide sequence Nuc encoding the site-specific nuclease system operably linked to the second promoter P2.

[0019] [7] The DNA editing method according to any one of [1] to [6], wherein the introduction of the vector and site-specific nuclease system into the cell is the introduction of an integrated vector comprising: a first promoter P1; a structure (1); a second promoter P2; and a nucleotide sequence Nuc encoding the site-specific nuclease system operably linked to the second promoter P2; the structure (3) produced in the cleavage step further comprises P2 and Nuc operably linked to P2; and the selection step is a step in which the 3' end of M1 and the 5' end of M2 in the fragment represented by structure (3) are joined to obtain a selection vector that is operably linked to P1 and contains a functional selection marker gene and Nuc operably linked to P2.

[0020] [8] The DNA editing method described in [7], wherein the integrated vector further comprises an autonomously replicating sequence CEN / ARS, the structure (3) produced in the cleavage step further comprises CEN / ARS, and the selection step is a step in which the 3' end of M1 and the 5' end of M2 in the fragment represented by structure (3) are joined to obtain a selection vector that is operably linked to P1 and contains a functional selection marker gene, CEN / ARS, and Nuc operably linked to P2.

[0021] [9] The DNA editing method according to any one of [6] to [8], wherein the nucleotide sequence Nuc encoding the site-specific nuclease system is a nucleotide sequence encoding a fusion protein of a DNA-binding domain and a nuclease domain.

[0022]

[10] The DNA editing method according to any one of [6] to [8], wherein the nucleotide sequence Nuc encoding the site-specific nuclease system is a nucleotide sequence encoding a Cas protein and a nucleotide sequence encoding its guide RNA.

[0023]

[11] A method for producing DNA-edited cells in which a desired nucleotide sequence has been inserted into a target site of a target DNA or in which the target site has been removed, the cell production method comprising: a step of obtaining cells in which the desired nucleotide sequence D has been inserted into the target site or the target site has been removed by the DNA editing method according to any one of [1] to

[10] and which contain the selection vector; and a step of selecting DNA-edited cells in which the desired nucleotide sequence D has been inserted into the target site or the target site has been removed, using the selection marker gene contained in the selection vector as an index.

[0024]

[12] The cell production method described in

[11] , wherein the vector further comprises an autonomously replicating sequence CEN / ARS, and further comprises a step of culturing the DNA-edited cells to remove the selection vector from the cells.

[0025]

[13] A vector for inserting a desired nucleotide sequence into a target site in a target DNA or for removing the target site by a site-specific nuclease system, comprising a first promoter P1, and the following structure (1'): 5'-M1-Hv1'-D'-Hv2'-M2-3' ... (1'). [In (1'), M1 represents a 5' fragment of a nucleotide sequence encoding a selectable marker gene and is operably linked to a first promoter P1; Hv1' represents a nucleotide sequence homologous to a first nucleotide sequence Ht1 on the 5' side of the target site of the target DNA or an insertion site thereof; D' represents the desired nucleotide sequence or an insertion site thereof, but may be absent; Hv2' represents a nucleotide sequence homologous to a second nucleotide sequence Ht2 on the 3' side of the target site of the target DNA or an insertion site thereof; M2 represents the remaining 3' fragment of the nucleotide sequence encoding the selectable marker gene; and adjacent sequences in M1, Hv1', D', Hv2', and M2 may partially overlap each other. and a fragment having the following structure (2'): 5'-Hv1'-D'-Hv2'-3' ... (2') and a fragment having the following structure (3'): 5'-M2-P1-M1-3' ... (3') are generated by the site-specific nuclease system.

[0026]

[14] A DNA editing vector according to

[13] , further comprising an autonomously replicating sequence CEN / ARS, wherein the site-specific nuclease system generates a fragment further comprising CEN / ARS as the structure (3').

[0027]

[15] The following structure (11') may be used as the structure (1'): 5'-M1-T1'-Hv1'-D'-Hv2'-T2'-M2-3' ... (11') [In (11'), T1' represents a TALEN_1 binding region or an insertion site thereof, comprising a first DNA-binding domain recognition sequence or its complementary sequence L1, and a second DNA-binding domain recognition sequence or its complementary sequence R1; T2' represents a TALEN_2 binding region or an insertion site thereof, comprising a third DNA-binding domain recognition sequence or its complementary sequence L2, and a fourth DNA-binding domain recognition sequence or its complementary sequence R2; M1, Hv1', D', Hv2', and M2 are each as defined in the structure (1'); and in M1, T1', Hv1', D', Hv2', T2', and M2, adjacent sequences may partially overlap with each other. ], wherein the site-specific nuclease system comprises TALENs comprising a DNA-binding domain and a nuclease domain: TALEN_1 comprising a first DNA-binding domain and a second DNA-binding domain, and generating the 5'-end of structure (2'); TALEN_2 comprising a third DNA-binding domain and a fourth DNA-binding domain, and generating the 3'-end of structure (2'); and TALEN_3 comprising a fifth DNA-binding domain that recognizes a nucleotide sequence on the 5'-side of region T3 containing the target site of the target DNA as a fifth DNA-binding domain recognition sequence or its complementary sequence L3, and a sixth DNA-binding domain that recognizes a nucleotide sequence on the 3'-side of region T3 as a sixth DNA-binding domain recognition sequence or its complementary sequence R3, and cleaves the target site or its vicinity in the target DNA.

[0028]

[16] A structure (1') comprises a first guide RNA recognition sequence or its complementary sequence or its insertion site G1', and a second guide RNA recognition sequence or its complementary sequence or its insertion site G2', wherein G1' is between M1 and Hv1' and may overlap with at least one of M1 and Hv1', and G2' is between M2 and Hv2' and may overlap with at least one of M2 and Hv2', and the site-specific nuclease system is a CRISPR-Cas system comprising a Cas protein and its guide RNA, wherein: CRISPR-Cas system_1 comprises a first guide RNA, and the Cas protein generates the 5' end of structure (2'); and CRISPR-Cas system_2 comprises a second guide RNA, and the Cas protein generates the 3' end of structure (2'); The DNA editing vector according to

[13] or

[14] , which comprises a CRISPR-Cas system_3, which comprises a third guide RNA that recognizes a nucleotide sequence present so as to include the target site of the target DNA as a third guide RNA recognition sequence or its complementary sequence G3, and in which a Cas protein cleaves the target site or its surroundings in the target DNA.

[0029]

[17] A DNA editing vector according to any one of

[13] to

[16] , which is an integrated vector comprising a first promoter P1, a structure (1'), a second promoter P2, and a nucleotide sequence Nuc encoding the site-specific nuclease system operably linked to the second promoter P2, wherein the site-specific nuclease system generates a fragment further comprising P2 and Nuc operably linked to P2 as structure (3').

[0030]

[18] A DNA editing vector according to any one of

[13] to

[17] , wherein M1 and M2 are nucleotide sequences in which the selectable marker gene is split so that the 3' end of M1 and the 5' end of M2 of the fragment represented by the structure (3') can be linked and function.

[0031]

[19] The DNA editing vector described in

[18] , wherein the 3' end of M1 and the 5' end of M2 are nucleotide sequences that overlap with each other, and the selection marker gene functions by binding the 3' end of M1 and the 5' end of M2 via the overlapping nucleotide sequence.

[0032]

[20] The DNA editing vector according to

[19] , wherein the length of the overlapping nucleotide sequence is 40 to 500 bases.

[0033]

[21] A DNA editing vector according to

[20] , wherein a stop codon is added to the 3' end of M1 and / or the 5' end of M2, and the stop codon is removed from M1 and / or M2 by binding via the overlapping nucleotide sequence.

[0034]

[22] A DNA editing kit comprising the DNA editing vector according to any one of

[13] to

[21] and the site-specific nuclease system.

[0035]

[23] The DNA editing kit described in

[22] , wherein the site-specific nuclease system is a nuclease system expression vector comprising an autonomously replicating sequence CEN / ARS, a second promoter P2, and a nucleotide sequence Nuc encoding the site-specific nuclease system operably linked to the second promoter P2.

[0036] According to the present invention, it is possible to provide a DNA editing method that can accurately and efficiently insert a desired nucleotide sequence into a target site of target DNA in a cell using a vector or remove the target site, a cell production method using the same, and a DNA editing vector and a DNA editing kit for use in these methods.

[0037] Furthermore, when the vector contains the autonomously replicating sequence CEN / ARS, it is further possible to provide a DNA editing method that can insert a desired nucleotide sequence into a target site of a target DNA using the vector or remove the target site from the target DNA, and then drop the vector to highly efficiently obtain genomic DNA-edited cells in which foreign genes other than the inserted nucleotide sequence have been removed, a cell production method using the same, and a DNA editing vector and a DNA editing kit for use in these methods.

[0038]

[0023] Figure 1 is a schematic diagram showing one embodiment of insertion of a nucleotide sequence into target DNA by a vector in the DNA editing method of the present invention. (a) is a schematic diagram showing the configuration of a DNA editing vector and target DNA in the DNA editing method of the present invention, (b) is a schematic diagram showing the configuration of a selection vector formed in the DNA editing method of the present invention, and (c) is a schematic diagram showing the configuration of DNA into which the nucleotide sequence has been inserted (edited DNA) by the DNA editing method of the present invention.

[0024] Figure 1 is a schematic diagram showing one embodiment of removal of a target site (target) from target DNA by a vector in the DNA editing method of the present invention. 1A is a schematic diagram showing the configuration of a DNA editing vector and target DNA in the DNA editing method of the present invention; (b) is a schematic diagram showing the configuration of a selection vector formed in the DNA editing method of the present invention; and (c) is a schematic diagram showing the configuration of DNA (edited DNA) from which the target site has been removed by the DNA editing method of the present invention. A schematic diagram showing one embodiment of the configuration of a DNA editing vector and target DNA in the DNA editing method of the present invention. (a) shows a preferred configuration of a DNA editing vector and target DNA when a TALEN is used as the site-specific nuclease system, and (b) shows one embodiment of the preferred configuration of a DNA editing vector and target DNA when a CRISPR-Cas system is used as the site-specific nuclease system. 1 is a schematic diagram showing one embodiment of removal of a selection vector in the DNA editing method of the present invention, illustrating the combination of a DNA editing vector and a nuclease system expression vector when introduced into a cell and the resulting state of cell life and death. 2 is a schematic diagram showing one embodiment of removal of a selection vector in the DNA editing method of the present invention, illustrating the state inside the cell when a DNA editing vector and a nuclease system expression vector are introduced into a cell and editing of the target site occurs (left), and the state when the selection vector is removed from the cell (right).1 is a schematic diagram showing a preferred embodiment when the DNA editing vector in the DNA editing method of the present invention is an all-in-one NICS vector. It is a schematic diagram showing the DNA editing method constructed in Test Example 1. It is a schematic diagram (a) showing the positions where primers were designed in the PCR reaction performed in Test Example 1, and an electrophoresis photograph (b) of the amplified product after the PCR reaction. It is a schematic diagram showing the structure of the plasmid "pMD20-ARS-aphVIII-sep-BamHI" used to prepare each vector in Test Example 2. It is a schematic diagram (a) showing the structure of the validation vector_NoNR prepared in (1) Verification Test 1 of Test Example 2, and a schematic diagram (b) showing the structure of the vector when the validation vector_NoNR is cleaved to express paromomycin resistance. 1 is a graph showing the number of colonies measured in Test Example 2 (1) Verification Test 1. It is a schematic diagram (a) showing the positions where primers were designed in the PCR reaction performed in Test Example 2 (1) Verification Test 1, and an electrophoresis photograph (b) of the amplified product after the PCR reaction. It is a graph showing the number of colonies measured in Test Example 2 (2) Verification Test 2. It is a schematic diagram (a) showing the structure of the pNICS36 vector (or pNICS210 vector) and the structure of the TALEN vector_PDAT1 prepared in Test Example 2 (3) Construction of the NICS vector, and a schematic diagram (b) showing the structure of the all-in-one NICS36 vector (or all-in-one NICS210 vector). 1 is a graph showing the number of colonies measured in (4) a test of introducing a NICS vector into cells in Test Example 2. 2 is a schematic diagram showing the positions at which primers were designed in the PCR reaction carried out in (5) PCR analysis and sequence analysis in Test Example 2. 3 is an electrophoresis photograph of the amplification product after the PCR reaction carried out on paromomycin-resistant colonies formed by introducing a combination of the pNICS210 vector and the TALEN vector_PDAT1 in (5) PCR analysis and sequence analysis in Test Example 2.

[0039] Figure 1 is an electrophoretic photograph of the amplification product after PCR reaction performed on paromomycin-resistant colonies formed by introducing the all-in-one NICS210 vector in (5) PCR analysis and sequence analysis of Test Example 2.

[0040] Figure 2 is an external view showing the growth status of each of the strains (6 strains each) that grew on F2N plates (F2N) but did not grow on plates containing paromomycin (F2N+Paro) in (6) CEN / ARS vector elimination test of Test Example 2, using paromomycin-resistant colonies No. 5 and No. 8 formed by introducing the all-in-one NICS210 vector. 14. This is an electrophoretic photograph of the amplified products after PCR reaction using primers that detect FokI and DNA extracted using a simple DNA extraction kit from colonies No. 5 and No. 8 (strains before vector loss) and six strains derived from these colonies (vector-loss strains) confirmed in FIG. 14 as templates. This is an electrophoretic photograph of the amplified products after PCR reaction using primers that detect FokI, the N-terminal domain of TALEN (TALEN-N), the paromomycin resistance gene (Paromomycin resistance gene (ParoR)), the kanamycin resistance gene (KanR), and PDAT1 as templates. This is a schematic diagram showing one embodiment of the application of the DNA editing method (NICS system) of the present invention.

[0023] Figure 1 is a schematic diagram showing the case where two types of nucleotide sequences (X, Y) are inserted in one embodiment of the DNA editing method (NICS system) of the present invention. Figure 2 is a schematic diagram showing the detailed structure of the "all-in-one NICS210 vector" prepared in (3) Construction of the NICS vector in Test Example 2. Figure 3 is an electrophoresis photograph of the amplification product after PCR reaction performed on paromomycin-resistant colonies formed by introducing the all-in-one NICS210-GPAT1 vector in (2) Test of introducing the NICS vector into cells.

[0039] Figure 1 shows the appearance of each of the six strains (six strains each) that grew on F2N plates (F2N) but did not grow on plates containing paromomycin (F2N + Paro) in Test Example 3 (3) CEN / ARS vector elimination test using paromomycin-resistant colonies No. 3 and No. 4 formed by introducing the all-in-one NICS210-GPAT1 vector.

[0040] Figure 1 shows an electrophoretic photograph of the amplification product after PCR performed on paromomycin-resistant colonies formed by introducing the all-in-one NICS400 vector in Test Example 4 (2) NICS vector introduction test into cells. 5 shows a schematic diagram (upper row) illustrating the configuration of the NICS vector prepared in (1) Construction of the NICS vector and the configuration of the CRISPR / Cas9 vector; a schematic diagram (lower left) illustrating the configuration of the vector when the NICS vector is cleaved and puromycin resistance is expressed; and a schematic diagram (lower right) illustrating the state when insertion of a knock-in fragment (3x Flag tag sequence) into the target site occurs. (2) A graph illustrating the viability obtained in the verification test of Test Example 5. (3) A graph illustrating the viability under each puromycin concentration for each combination of the NICS vector (pNICS60-PARP1 vector, pNICS192-PARP1 vector) and the CRISPR / Cas9 vector targeting PARP1 in the introduction test of the NICS vector into cells of Test Example 5. 1 is a graph showing the viability at each puromycin concentration for each combination of a NICS vector (pNICS192-ATP5B vector) and a CRISPR / Cas9 vector targeting ATP5B in Test Example 5 (3) Cellular introduction test of a NICS vector. 2 is an electrophoresis photograph of the amplification product after PCR reaction performed on colonies formed under each puromycin concentration after introduction of a NICS vector (pNICS60-PARP1 vector) and a CRISPR / Cas9 vector targeting PARP1 in Test Example 5 (2) PCR analysis.In Test Example 5 (2) PCR analysis, a NICS vector (pNICS192-PARP1 vector) and a CRISPR / Cas9 vector targeting PARP1 were introduced, and the colonies formed under each puromycin concentration were analyzed by PCR. This is an electrophoretic photograph of the amplification product after the PCR reaction. In Test Example 5 (2) PCR analysis, a NICS vector (pNICS60-ATP5B vector) and a CRISPR / Cas9 vector targeting ATP5B were introduced, and the colonies formed under each puromycin concentration were analyzed by PCR. This is an electrophoretic photograph of the amplification product after the PCR reaction. In Test Example 5 (2) PCR analysis, a NICS vector (pNICS192-ATP5B vector) and a CRISPR / Cas9 vector targeting ATP5B were introduced, and the colonies formed under each puromycin concentration were analyzed by PCR. This is an electrophoretic photograph of the amplification product after the PCR reaction. FIG. 10 is a graph showing the HDR efficiency in colonies formed under each puromycin concentration for each combination of a NICS vector (pNICS192-PARP1 vector) and a CRISPR / Cas9 vector targeting PARP1 in Test Example 5 (3) TIDER analysis.

[0039] The present invention will be described in detail below with reference to preferred embodiments. While preferred aspects of the present invention will be described with reference to the drawings, the present invention is not limited thereto. In the following description and drawings, identical or corresponding elements are designated by the same reference numerals, and redundant explanations will be omitted.

[0040] <DNA Editing Method / NICS> The DNA editing method of the present invention is a method for inserting a desired nucleotide sequence into a target site in target DNA in a cell, or for removing the target site from target DNA. Here, "insertion" of the desired nucleotide sequence also includes sequence swapping, in which the target site is removed and the desired nucleotide sequence is inserted therein. The DNA editing method of the present invention includes an introduction step of introducing a vector and a site-specific nuclease system into a cell and contacting them with target DNA, wherein the vector comprises a first promoter P1, and the following structure (1): 5'-M1-Hv1-D-Hv2-M2-3' ... (1) [in (1), M1 represents a 5' fragment of a nucleotide sequence encoding a selectable marker gene and is operably linked to the first promoter P1, Hv1 represents a nucleotide sequence homologous to a first nucleotide sequence Ht1 on the 5' side of the target site of the target DNA, D represents the desired nucleotide sequence but is optional, Hv2 represents a nucleotide sequence homologous to a second nucleotide sequence Ht2 on the 3' side of the target site of the target DNA, and M2 represents the remaining 3' fragment of the nucleotide sequence encoding the selectable marker gene, and adjacent sequences in M1, Hv1, D, Hv2, and M2 may partially overlap each other. and a cutting step of generating from the vector a fragment represented by the following structure (2): 5'-Hv1-D-Hv2-3' ... (2) and a fragment represented by the following structure (3): 5'-M2-P1-M1-3' ... (3) from the vector by the site-specific nuclease system, and cutting the target site or its periphery in the target DNA; an editing step of binding the target DNA and the fragment represented by structure (2) depending on the homology between Ht1 and Hv1, and binding depending on the homology between Ht2 and Hv2, thereby inserting a desired nucleotide sequence D into the target site or removing the target site; and a selection step of binding the 3' end of M1 and the 5' end of M2 in the fragment represented by structure (3) to obtain a selection vector operably linked to P1 and containing a functional selection marker gene.

[0041] (Target DNA) In the present invention, a target site for inserting or removing a desired nucleotide sequence is referred to as a target site, and DNA containing the target site is referred to as "target DNA." The target DNA according to the present invention is double-stranded DNA, and for the purpose of illustrating its correspondence with the DNA editing vector and site-specific nuclease system described below, the target DNA is defined as having a structure in which the 5' side of the target site of at least one strand is designated as a first nucleotide sequence (Ht1) and the 3' side of the target site is designated as a second nucleotide sequence (Ht2), and these are included.

[0042] As one embodiment of the target DNA configuration, a schematic diagram of a target site for inserting a desired nucleotide sequence is shown in the lower part of Figure 1A(a). In this case, the first nucleotide sequence (Ht1) and the second nucleotide sequence (Ht2) are preferably adjacent to each other in the target DNA, but may be separated by a region of several bases, preferably 1 to 10,000 bases, more preferably 1 to 3,000 bases, and even more preferably 1 to 1,000 bases, as shown in Figure 1A(a).

[0043] As one embodiment of the target DNA configuration, a schematic diagram of a case where the nucleotide sequence to be removed is the target site is shown in the lower part of Figure 1B (a). In this case, the length of the target site (target in Figure 1B (a)) is 1 to 10,000 bases, more preferably 1 to 3,000 bases, and even more preferably 1 to 1,000 bases. In this case, Ht1 is adjacent to the 5' end of the target site, and Ht2 is adjacent to the 3' end. In this specification, the term "base" indicating the length of a nucleotide sequence is synonymous with "nucleotide" or, when double-stranded, "bp."

[0044] In Figures 1A(a) and 1B(a), the target DNA of the present invention has been cleaved at the target site by a site-specific nuclease (arrow). However, the cleavage site may not be the target site, but may be in the vicinity thereof, and may be on the first nucleotide sequence (Ht1) or the second nucleotide sequence (Ht2). In the present invention, Ht1 and Ht2 are set as described above, and a DNA editing vector containing the corresponding Hv1 and Hv2 described below is designed. Binding occurs depending on the homology between Ht1 and Hv1 and between Ht2 and Ht2, thereby obtaining a sequence in which a desired nucleotide sequence is inserted between Ht1 and Ht2, or a sequence in which the target site has been removed from between Ht1 and Ht2. In the target DNA of the present invention, the length between the cleavage site and the target site is preferably within 400 bases, more preferably 0 to 200 bases, depending on the lengths of Ht1 and Ht2.

[0045] Furthermore, when the site-specific nuclease of the present invention is a TALEN as described below, in order to show the correspondence with such a TALEN, the target DNA of the present invention is defined as having a structure in which the strand containing Ht1 and Ht2 further contains a TALEN_3 binding region T3 as a region containing the target site or at least partially overlapping the target site. A schematic diagram showing one embodiment of the target DNA configuration when the site-specific nuclease system of the present invention is a TALEN (when the target site is the site into which the desired nucleotide sequence is to be inserted) is shown in the lower part of Figure 1C (a). In Figure 1C (a), T3 is sandwiched between Ht1 and Ht2, but as described above, Ht1 and Ht2 may be adjacent to each other, and part or all of T3 may overlap with a portion of the 3'-end of Ht1 and / or a portion of the 5'-end of Ht2. When the nucleotide sequence to be removed is the target site, the length of the target site is as described above.

[0046] For convenience, T3 is assumed to comprise, from the 5'-end, a fifth DNA-binding domain recognition sequence or its complementary sequence L3, a spacer S3, and a sixth DNA-binding domain recognition sequence or its complementary sequence R3, arranged adjacently in this order. The fifth DNA-binding domain (TALE of Left-TALEN) of TALEN_3 is designed to bind to L3, and the sixth DNA-binding domain (TALE of Right-TALEN) is designed to bind to R3, thereby causing cleavage (arrow) within S3 by the nuclease activity of TALEN_3. However, as described above, the cleavage site may not be the target site, but may be on the first nucleotide sequence (Ht1) or the second nucleotide sequence (Ht2). Each DNA-binding domain recognition sequence is a sequence recognized by each DNA-binding domain (fifth DNA-binding domain, sixth DNA-binding domain) of TALEN_3 described below. Typically, Left-TALEN and Right-TALEN bind to opposite strands, and therefore, L3 and R3 are in a relationship such that when one is a DNA-binding domain recognition sequence, the other is a complementary sequence to the DNA-binding domain recognition sequence. The lengths of L3 and R3 are each independently 10 to 30 bases, preferably 13 to 25 bases, and more preferably 15 to 20 bases. The length of S3 is 10 to 20 bases, preferably 12 to 19 bases, and more preferably 15 to 16 bases.

[0047] Furthermore, when the site-specific nuclease according to the present invention is the CRISPR-Cas system described below, in order to show its correspondence with the CRISPR-Cas system, the target DNA according to the present invention is assumed to have a structure in which at least one strand further comprises a third guide RNA recognition sequence or its complementary sequence, G3. A schematic diagram showing one embodiment of the target DNA configuration when the site-specific nuclease system according to the present invention is the CRISPR-Cas system (when the target site is the site into which the desired nucleotide sequence is to be inserted) is shown in the lower part of Figure 1C (b). In Figure 1C (b), Ht1 and Ht2 are spaced apart, but as described above, Ht1 and Ht2 may be adjacent to each other. Furthermore, even if G3 is sandwiched between Ht1 and Ht2, part or all of G3 may overlap with a portion of the 3'-end of Ht1 and / or a portion of the 5'-end of Ht2. When the nucleotide sequence to be removed is the target site, the length of the target site is as described above. The CRISPR-Cas system preferably cleaves the region between Ht1 and Ht2 as a target site (arrow). In the CRISPR-Cas system, the Cas protein cleaves a site contained in the guide RNA recognition sequence, so G3 exists so as to include the target site or its complementary sequence.

[0048] For example, in the case of the CRISPR-Cas system, the third guide RNA is designed to recognize a third guide RNA recognition sequence that is G3 or its complementary sequence, and the Cas9 protein is designed to recognize a sequence located 3' of the complementary sequence of the third guide RNA recognition sequence as a PAM sequence, thereby allowing the target site to be cleaved by the Cas9 protein. The length of the guide RNA recognition sequence or its complementary sequence is 12 to 50 bases, preferably 17 to 30 bases, and more preferably 17 to 25 bases. Note that the PAM sequence varies depending on the type of Cas protein, and typical PAM sequences are known. However, it is possible to expand the range of target site options by modifying the Cas protein (e.g., by introducing a mutation) to alter PAM recognition.

[0049] The base sequence of such target DNA is not particularly limited, and by designing the DNA editing vector and site-specific nuclease system described below to match the sequence, it can be used as a target for the DNA editing method of the present invention.

[0050] Furthermore, the target DNA according to the present invention may be either intranuclear or extranuclear DNA, depending on the purpose, and may be endogenous or exogenous DNA. Endogenous DNA includes genomic DNA, and exogenous DNA includes, for example, DNA introduced into a cell.

[0051] (Cells) The cells in which the target DNA is present, i.e., the cells to be subjected to the DNA editing method of the present invention, are not particularly limited and may be eukaryotic or prokaryotic cells, but are preferably eukaryotic cells. Examples of the eukaryotic cells include animal cells (e.g., cells of mammals, fish, birds, reptiles, amphibians, insects), plant cells, algae cells, slime molds, and fungi (e.g., yeast). Examples of the prokaryotic cells include Escherichia coli, Salmonella, Bacillus subtilis, lactic acid bacteria, extreme thermophiles, actinomycetes, and archaea.

[0052] "Animal cells" include, for example, cells constituting an individual animal, cells constituting organs or tissues extracted from an animal, and cultured cells derived from animal tissues. Specific examples include germ cells such as oocytes and sperm; embryonic cells at various stages of embryonic development (e.g., 1-cell, 2-cell, 4-cell, 8-cell, 16-cell, and morula stages); stem cells such as induced pluripotent stem (iPS) cells and embryonic stem (ES) cells; and somatic cells such as fibroblasts, hematopoietic cells, neurons, muscle cells, bone cells, liver cells, pancreatic cells, brain cells, and kidney cells. Pre- and post-fertilization oocytes can be used as the oocytes targeted by the DNA editing method, but fertilized oocytes, i.e., fertilized eggs, are preferred. Particularly preferred are pronuclear stage embryos. Oocytes can be used by thawing cryopreserved oocytes.

[0053] "Plant cells" include, for example, cells that constitute an individual plant, cells that constitute organs or tissues separated from a plant, cultured cells derived from plant tissue, etc. Examples of plant organs and tissues include leaves, stems, shoot tips (growing points), roots, tubers, calluses, etc.

[0054] Among these, the cells according to the present invention are preferably at least one type selected from the group consisting of algal cells and animal cells, and the algal cells are more preferably unicellular algae such as Nannochloropsis, Chlamydomonas, Euglena, Chlorella, Botryococcus, diatoms, coccolithophorids, cyanobacteria, Cyanidioschyzon, Pseudococcomixa, Spirulina, and Haematococcus.

[0055] (Site-specific nuclease system) In the present invention, the term "site-specific nuclease system" refers to a system that includes a nuclease that cleaves double-stranded DNA and that can be controlled so that cleavage by the nuclease occurs specifically at a target site. Examples of such site-specific nuclease systems include a system (TALEN) in which a nuclease is fused to a TAL effector (TALE), a system in which a nuclease is fused to a zinc finger (ZF), and a CRISPR-Cas system. In the present invention, a TALEN and / or a CRISPR-Cas system is preferred.

[0056] [TALEN] A TALEN (transcription activator-like effector nuclease) is a fusion protein in which the type IIS restriction enzyme FokI serves as the nuclease domain and a TALE serves as the DNA-binding domain. The DNA-binding domains of a pair of TALENs (Left-TALEN and Right-TALEN) bind to opposite strands of the target DNA, and FokI dimerizes with each other, thereby exerting site-specific double-strand cleavage activity (nuclease activity) in DNA and cleaving the region between the pair of DNA-binding domains. Typical nucleotide sequences encoding FokI are known, but may be appropriately modified. Such TALENs may be known or modified as appropriate. Furthermore, methods for adjusting the amino acid sequence of each DNA-binding domain are known, and a person skilled in the art can design a DNA-binding domain that can recognize and bind to a nucleotide sequence on a target DNA (DNA-binding domain recognition sequence), as well as a nucleotide sequence encoding the same, based on the nucleotide sequence on the target DNA (DNA-binding domain recognition sequence).

[0057] When TALENs are used in the present invention, such TALENs include TALEN_1 comprising a first DNA-binding domain and a second DNA-binding domain, TALEN_2 comprising a third DNA-binding domain and a fourth DNA-binding domain, and TALEN_3 comprising a fifth DNA-binding domain and a sixth DNA-binding domain.

[0058] TALEN_1 and TALEN_2 recognize T1 and T2 on the DNA editing vector corresponding to each DNA binding domain, respectively, and cleave the DNA editing vector at S1 between L1 and R1 and S2 between L2 and R2. TALEN_3 recognizes T3 on the target DNA and cleaves the target DNA at S3 between L3 and R3. Note that the location where the target DNA is cleaved is the target site or its vicinity.

[0059] The first DNA-binding domain, the third DNA-binding domain, and the fifth DNA-binding domain may be the same as each other, and the second DNA-binding domain, the fourth DNA-binding domain, and the sixth DNA-binding domain may be the same as each other, and TALEN_1, TALEN_2, and TALEN_3 may be the same as each other. Using one common TALEN as the three types of TALEN enables DNA to be cleaved more easily and efficiently. For example, a fifth DNA-binding domain that recognizes L3 on the 5' side of the region (T3) containing the target site of the target DNA and a sixth DNA-binding domain that recognizes R3 on the 3' side are designed, and TALEN_3 is designed to cleave the target DNA at S3 between L3 and R3 (FIG. 1C (a)). In accordance with this, by designing a DNA editing vector so that the sequences of T1 and T2 are the same as those of T3, only one type of TALEN_3 can be used as TALEN_1 and TALEN_2.

[0060] [CRISPR-Cas System] The CRISPR-Cas system according to the present invention comprises, as its components, at least a Cas protein and its guide RNA. The guide RNA consists of a crRNA (CRISPR RNA) having a base sequence complementary to a target base sequence (guide RNA recognition sequence) and a tracrRNA (trans-activating crRNA). The crRNA further contains a base sequence on the 3' end that can interact (hybridize) with the tracrRNA. Meanwhile, the tracrRNA contains a base sequence on the 5' end that can interact (hybridize) with a partial base sequence of the crRNA. Thus, the guide RNA forms a double-stranded RNA that interacts with the Cas protein through the interaction of these base sequences. Therefore, by introducing a Cas protein and its guide RNA into a cell, the guide RNA binds to the guide RNA recognition sequence of the DNA, and guides the Cas protein, which forms a complex with the guide RNA, to the DNA. The induced Cas protein then recognizes the PAM sequence located 3' to the complementary sequence of the guide RNA recognition sequence and cleaves the target site in the DNA using its nuclease activity.

[0061] The CRISPR-Cas system may be any of Class 1, in which a complex is formed between a guide RNA and one Cas protein to cleave nucleic acids, and Class 2, in which a complex (cascade complex) is formed between a guide RNA and multiple Cas proteins to cleave nucleic acids, and may be any of Type I, Type II, Type III, Type IV, Type V, and Type VI. Among these, Class 2 is preferred from the standpoint of ease, and a CRISPR-Cas9 system in which the Cas protein is a Cas9 protein is more preferred. The configurations of each of these CRISPR-Cas systems and the typical nucleotide sequences encoding each Cas protein are all publicly known, but they may be appropriately modified, and publicly known systems or systems similar thereto may be used as appropriate. For example, the Cas protein may be appropriately modified, such as by introducing a mutation to alter its recognition of the PAM sequence.

[0062] Various methods are known for designing the PAM sequence and guide RNA recognition sequence of such Cas proteins, for example, E-CRISP (http: / / www.e-crisp.org / E-CRISP / ), CRISPRdirect (http: / / crispr.dbcls.jp / ) (University of Tokyo), Guide RNA Target Design Tool. (https: / / www.blueheronbio.com / external / tools / gRNASrc.jsp) (Blue Heron Biotech) and the like can be used to design.

[0063] When a CRISPR-Cas system is used in the present invention, the CRISPR-Cas system includes a CRISPR-Cas system 1 including a first guide RNA, a CRISPR-Cas system 2 including a second guide RNA, and a CRISPR-Cas system 3 including a third guide RNA.

[0064] CRISPR-Cas system_1 and CRISPR-Cas system_2 recognize G1 and G2 on the DNA editing vector corresponding to each guide RNA, respectively, and cleave the DNA editing vector at G1 and G2, respectively. CRISPR-Cas system_3 recognizes G3 on the target DNA and cleaves the target DNA at G3.

[0065] The first guide RNA, second guide RNA, and third guide RNA may be the same as each other, and CRISPR-Cas system_1, CRISPR-Cas system_2, and CRISPR-Cas system_3 may also be the same as each other. Using a single common CRISPR-Cas system for the three types of CRISPR-Cas systems enables DNA to be cleaved more easily and efficiently. For example, a third guide RNA that recognizes a region (G3) containing the target site of the target DNA described above and a Cas9 protein that binds to the third guide RNA and recognizes the PAM sequence located 3' to the complementary sequence of the third guide RNA recognition sequence are designed, and CRISPR-Cas system_3 is designed to cleave the target DNA at G3 ((b) of FIG. 1C ). In accordance with this, by designing a DNA editing vector so that the sequences of G1 and G2 are the same as or complementary to G3 and contain a PAM sequence or its complementary sequence, only one type of CRISPR-Cas system 3 can be used as CRISPR-Cas system 1 and CRISPR-Cas system 2.

[0066] (DNA Editing Vector / NICS Vector) The vector used in the DNA editing method of the present invention (sometimes referred to herein as the "DNA editing vector" or "NICS vector") is a vector comprising a first promoter P1 and the following structure (1): 5'-M1-Hv1-D-Hv2-M2-3' ... (1) Preferred embodiments of the configuration of the DNA editing vector used in the DNA editing method of the present invention are shown in Figure 1A(a) when the target site is a site into which a desired nucleotide sequence is to be inserted, i.e., when the DNA editing method of the present invention is a DNA insertion method (knock-in method), and in Figure 1B(a) when the target site is a nucleotide sequence to be removed, i.e., when the DNA editing method of the present invention is a DNA removal method (knock-out method).

[0067] Preferably, the vector used in the DNA editing method of the present invention further comprises an autonomously replicating sequence, CEN / ARS. CEN / ARS stands for "centromere and autonomous replication sequence," and is a sequence involved in the chromosomal stability of budding yeast. It is commonly used as an autonomously replicating sequence in vectors for budding yeast. It has been reported that vectors containing this CEN / ARS are maintained intracellularly in diatoms and unicellular algae (e.g., Nannochloropsis). Such vectors containing CEN / ARS can be eliminated from host cells by repeated culture of the host cells (Non-Patent Document 3, etc.). The nucleotide sequence of such a CEN / ARS is typically represented by SEQ ID NO: 1, but the sequence may be appropriately modified as long as the function of the CEN / ARS (e.g., the replication function of the vector within the cell) is maintained.

[0068] The structure (1) contained in the DNA editing vector according to the DNA editing method of the present invention comprises M1, Hv1, D, Hv2, and M2 in this order from the 5' side.

[0069] In structure (1), M1 represents a 5' fragment of a nucleotide sequence encoding a selectable marker gene, M2 represents a 3' fragment of a nucleotide sequence encoding the selectable marker gene, and M1 and M2 are fragments obtained by splitting the selectable marker gene so that they can function after cleavage with site-specific nucleotides and then recombine. Here, "split in a functional manner" means that, in the nucleotide sequence encoding the split selectable marker gene, the 3' end of the 5' fragment and the 5' end of the 3' fragment can be joined together, allowing the original selectable marker gene to function (the 5' fragment alone or the 3' fragment alone (before joining) will not function). This can be appropriately designed by a person skilled in the art depending on the type of selectable marker gene. For example, preferably, the 5' fragment of the two nucleotide sequences encoding the selectable marker gene is designated M1, and a nucleotide sequence is added to the 5' end of the remaining 3' fragment so that its sequence overlaps with several bases at the 3' end of M1, thereby designing M2. That is, M1 and M2 are designed so that the 3'-end of M1 and the 5'-end of M2 have overlapping nucleotide sequences (overlapping sequences). This allows the 3'-end of M1 and the 5'-end of M2 to bind via this overlapping sequence, i.e., the overhanging end of M1 generated by intracellular cleavage and the complementary overhanging end of M2 bind complementarily to each other, allowing the selectable marker gene to function. The length of the overlapping nucleotide sequence (overlapping sequence) between the 3'-end of M1 and the 5'-end of M2 is preferably, for example, 40 bases or more, more preferably 40 to 500 bases, even more preferably 50 to 400 bases, even more preferably 70 to 300 bases, and particularly preferably 150 to 300 bases.

[0070] The selectable marker gene can be any gene that has been used in conventional DNA editing methods, and examples thereof include drug resistance genes and reporter genes. Examples of the drug resistance genes include ampicillin resistance gene, zeocin resistance gene, bleomycin resistance gene, paromomycin resistance gene, kanamycin resistance gene, neomycin resistance gene, emesin resistance gene, spectinomycin resistance gene, hygromycin resistance gene, chloramphenicol resistance gene, erythromycin resistance gene, and puromycin resistance gene. Examples of the reporter gene include green fluorescent protein (GFP), DsRed, mCherry, mOrange, mBanana, mStrawberry, mRaspberry, and mPlum. The nucleotide sequences encoding each selectable marker gene are known, and may be appropriately modified as long as their functions are maintained.

[0071] Among these, the selectable marker gene according to the present invention is preferably a drug resistance gene, and more preferably a paromomycin resistance gene, a hygromycin resistance gene, a neomycin resistance gene, or a puromycin resistance gene, from the viewpoint of enabling more accurate confirmation of vector elimination from cells in a drug-containing medium. For example, in the paromomycin resistance gene or puromycin resistance gene, by setting the overlapping nucleotide sequence between the 3'-end of M1 and the 5'-end of M2 (the overlapping sequence) to 50 to 300 bases (e.g., 207 bases in (a) of Figure 6B, and 60 or 192 bases in Figure 23), the 3'-end of M1 and the 5'-end of M2 resulting from cleavage within the cell are joined via the overlapping sequence, thereby expressing sufficient paromomycin resistance or puromycin resistance. The nucleotide sequences of M1 and M2 in this case are typically shown in SEQ ID NO: 3 and SEQ ID NO: 8, respectively, for a paromomycin resistance gene, and typically shown in SEQ ID NO: 43 and SEQ ID NO: 44, or SEQ ID NO: 43 and SEQ ID NO: 53, respectively, for a puromycin resistance gene, but are not particularly limited as long as they function as selectable marker genes when linked together, and may each be appropriately modified.

[0072] The lengths of M1 and M2 in structure (1) (including the overlapping sequence, if any) may be the same or different, and each independently is preferably 50 to 10,000 bases, more preferably 100 to 5,000 bases, even more preferably 200 to 3,000 bases, still more preferably 200 to 2,000 bases, and particularly preferably 300 to 2,000 bases.

[0073] In structure (1), it is more preferable that M1 and M2 have a stop codon added to the 3' end of M1 and / or the 5' end of M2, more preferably to both the 3' end of M1 and the 5' end of M2. This more reliably suppresses the expression of a selectable marker gene that has not been cleaved by the site-specific nuclease system. When the 3' end of M1 and the 5' end of M2 are cleaved intracellularly, this stop codon is typically removed from M1 and / or M2 by an intracellular repair system. This is particularly preferable because the 3' end of M1 and the 5' end of M2 are overlapping sequences, allowing removal by binding via the overlapping sequences.

[0074] In structure (1), Hv1 represents a nucleotide sequence homologous to a first nucleotide sequence Ht1 on the 5' side of the target site of the target DNA, and Hv2 represents a nucleotide sequence homologous to a second nucleotide sequence Ht2 on the 3' side of the target site of the target DNA. In the present invention, "homologous" preferably means that the nucleotide sequences are identical to each other (sequence identity of 100%), but also includes, for example, sequence identity of 85% or more, preferably 90% or more, 95% or more (e.g., 96% or more, 97% or more, 98% or more, 99% or more). From the perspective of DNA editing accuracy, the sequence identity between Hv1 and Hv2 is preferably 40% or less, and preferably 20% or less.

[0075] The lengths of Hv1 and Hv2 may be the same or different, and each independently is preferably 30 to 600 bases, more preferably 40 to 600 bases, even more preferably 100 to 500 bases, even more preferably 140 to 500 bases, even more preferably 150 to 450 bases, 150 to 400 bases, or 200 to 450 bases, and even more preferably 150 to 250 bases, or 200 to 300 bases. The present inventors have found that in the DNA editing method (preferably the DNA insertion method) of the present invention, DNA editing efficiency (preferably DNA insertion efficiency) is improved particularly in homologous sequences of lengths different from those of conventional homologous recombination (HR) and microhomology-mediated end joining (MMEJ), for example, 100 to 500 bases, preferably 200 to 450 bases, or even 200 to 400 bases.

[0076] When the DNA editing method of the present invention is a method for inserting a desired nucleotide sequence into a target site in target DNA (DNA insertion method), in structure (1), D represents the desired nucleotide sequence to be inserted into the target site. Such sequences are not particularly limited, and include various sequences such as promoters, terminators, enhancers, insulators, and binding sequences of expression control genes for controlling the expression of a gene of interest; fluorescent proteins, luminescent proteins, epitope tags, and the like for observing gene expression and localization; stop codons for gene disruption; mutant sequences for modifying gene function; and expression cassettes for expressing endogenous or exogenous genes. In this case, the length of D is preferably 1 to 10,000 bases, more preferably 5,000 bases or less, even more preferably 2,000 bases or less, and even more preferably 1,000 bases or less. When the DNA editing method of the present invention is a method for removing a target site from target DNA (DNA removal method), D is not included in structure (1) (i.e., the length of D is 0 bases). That is, Hv1 and Hv2 are adjacent to each other in structure (1).

[0077] In structure (1), adjacent sequences may partially overlap with each other. In this case, the length of the overlapping nucleotide sequence between M1 and Hv1, between Hv1 and D (in the case of the DNA insertion method), between D and Hv2 (in the case of the DNA insertion method), and between Hv2 and M2 is preferably 150 bases or less, more preferably 1 to 50 bases, and even more preferably 1 to 30 bases, respectively. When the 3'-end of M1 and the 5'-end of M2 are the overlapping sequences, the number of bases obtained by dividing the sum of the length of the overlapping nucleotide sequence between M1 and Hv1 and the length of the overlapping nucleotide sequence between Hv2 and M2 by the length of the overlapping sequence is preferably 40 bases or more, more preferably 50 bases or more, and even more preferably 150 bases or more.

[0078] In addition, in structure (1), adjacent sequences between M1 and Hv1, and between Hv2 and M2, may each be independently separated by a region of several bases, preferably 1 to 500 bases, more preferably 1 to 100 bases.

[0079] The DNA editing vector used in the DNA editing method of the present invention further comprises a first promoter P1, and M1 in structure (1) is operably linked to the first promoter P1. Here, "operably linked" between M1 and P1 means that the first promoter P1 is linked to M1 in structure (1) so as to enable expression of a selectable marker gene formed by the combination of M1 and M2; typically, P1 is positioned upstream of M1. The first promoter P1 and other control sequences are not particularly limited, and can be appropriately selected from constitutive promoters, tissue-specific promoters, stage-specific promoters, inducible promoters, CMV promoters, and the like, depending on the type of cells to be introduced. For example, when the cells of the present invention are Nannochloropsis cells, the Nannochloropsis LDSP promoter, Nannochloropsis LHC promoter, Nannochloropsis VCP1 promoter, Nannochloropsis TUB promoter, Nannochloropsis NR promoter, and the like can be used as P1. Furthermore, for example, when the cell according to the present invention is an animal cell, a CMV promoter or the like can be used as P1. Furthermore, the DNA editing vector according to the DNA editing method of the present invention may further contain other regulatory elements (e.g., terminators, enhancers, insulators, transcriptional regulatory factor expression cassettes, binding sequences for transcriptional regulatory factors), etc., as appropriate.

[0080] The DNA editing vector in the DNA editing method of the present invention is designed such that the site-specific nuclease system of the present invention produces a fragment having the following structure (2): 5'-Hv1-D-Hv2-3'...(2) and a fragment having the following structure (3): 5'-M2-P1-M1-3'...(3), or the cleavage site is designed to match the site-specific nuclease system.

[0081] For example, one embodiment of a DNA editing vector for the DNA editing method of the present invention, in which the site-specific nuclease of the present invention is a TALEN, is shown in the upper part of (a) of Figure 1C. When the site-specific nuclease of the present invention is a TALEN, the DNA editing vector for the DNA editing method of the present invention comprises the following structure (11) as structure (1): 5'-M1-T1-Hv1-D-Hv2-T2-M2-3' ... (11). In structure (11), M1, Hv1, D, Hv2, and M2 are as described above for structure (1). In structure (11), T1 is a TALEN_1 binding region comprising, adjacently from the 5'-terminus, a first DNA-binding domain recognition sequence or its complementary sequence L1, a spacer S1, and a second DNA-binding domain recognition sequence or its complementary sequence R1, in this order, and T2 is a TALEN_2 binding region comprising, adjacently from the 5'-terminus, a third DNA-binding domain recognition sequence or its complementary sequence L2, a spacer S2, and a fourth DNA-binding domain recognition sequence or its complementary sequence R2, in this order, where L1 and L2 may be the same as each other and may also be the same as L3 on the target DNA, and R1 and R2 may be the same as each other and may also be the same as R3 on the target DNA, and the TALEN_1 binding region, TALEN_2 binding region, and TALEN_3 binding region may be the same as each other. From the viewpoint of accuracy of DNA editing, the sequence identity between L1 and R1 and between L2 and R2 is preferably 40% or less, and more preferably 20% or less, respectively.

[0082] In TALEN_1, the first DNA-binding domain (TALE of Left-TALEN) is designed to bind to L1, the second DNA-binding domain (TALE of Right-TALEN) is designed to bind to R1, and in TALEN_2, the third DNA-binding domain (TALE of Left-TALEN) is designed to bind to L2, and the fourth DNA-binding domain (TALE of Right-TALEN) is designed to bind to R2. By each design, S1 and S2 are cleaved by the nuclease activity of each TALEN (arrows in Figure 1C(a)). Typically, Left-TALEN and Right-TALEN bind to opposite strands, and therefore the relationship between L1 and R1, and the relationship between L2 and R2, is such that when one is a DNA-binding domain recognition sequence, the other is a complementary sequence to the DNA-binding domain recognition sequence. The lengths of L1, R1, L2, and R2 are each independently 10 to 30 bases, preferably 13 to 25 bases, and more preferably 15 to 20 bases. The lengths of S1 and S2 are each independently 10 to 20 bases, preferably 12 to 19 bases, and more preferably 15 to 16 bases.

[0083] Preferably, M1 and L1, R1 and Hv1, Hv2 and L2, and R2 and M2 do not overlap with one another, but may overlap partially. In this case, the length of the overlapping nucleotide sequence is preferably 15 bases or less, more preferably 15 to 10 bases, and even more preferably 1 to 10 bases. When the 3'-end of M1 and the 5'-end of M2 are the overlapping sequences, the number of bases obtained by dividing the sum of the length of the overlapping nucleotide sequence between M1 and T1 and the length of the overlapping nucleotide sequence between T2 and M2 by the length of the overlapping sequences is preferably 40 bases or more, more preferably 50 bases or more, and even more preferably 150 bases or more.

[0084] In addition, in structure (11), M1 and L1, R1 and Hv1, Hv2 and L2, and R2 and M2 may each be separated independently by a region of several bases, preferably 1 to 500 bases, more preferably 1 to 100 bases.

[0085] Furthermore, for example, one embodiment of a DNA editing vector for the DNA editing method of the present invention, in which the site-specific nuclease of the present invention is the CRISPR-Cas system described below, is shown in the upper part of (b) of Figure 1C. When the site-specific nuclease of the present invention is the CRISPR-Cas system, the DNA editing vector for the DNA editing method of the present invention comprises a structure comprising a first guide RNA recognition sequence or its complementary sequence G1 and a second guide RNA recognition sequence or its complementary sequence G2 in addition to structure (1), preferably the following structure (12): 5'-M1-G1-Hv1-D-Hv2-G2-M2-3' ... (12).

[0086] In the CRISPR-Cas system, a site contained in the guide RNA recognition sequence is cleaved by the Cas protein, so in structure (12), G1 may be located between M1 and Hv1 and overlap with at least one of M1 and Hv1, and G2 may be located between M2 and Hv2 and overlap with at least one of M2 and Hv2. When the 3'-end of M1 and the 5'-end of M2 are the overlapping sequences, the number of bases obtained by dividing the sum of the length of the overlapping nucleotide sequence between M1 and G1 and the length of the overlapping nucleotide sequence between G2 and M2 by the length of the overlapping sequence is preferably 40 bases or more, more preferably 50 bases or more, and even more preferably 150 bases or more.

[0087] Furthermore, when the site-specific nuclease according to the present invention is a CRISPR-Cas system, the DNA editing vector according to the DNA editing method of the present invention also contains a PAM sequence recognized by the Cas protein. For example, in the case of a CRISPR-Cas9 system, the PAM sequence is located several bases away from the 3' end of the complementary strand of each guide RNA recognition sequence of G1 and G2.

[0088] G1 and G2 may be the same as each other and may also be the same as G3 on the target DNA. The length of G1 and G2 is independently 12 to 50 bases, preferably 17 to 30 bases, more preferably 17 to 25 bases.

[0089] The DNA editing vector used in the DNA editing method of the present invention may further comprise other components, for example, a nucleotide sequence encoding a selectable marker gene for confirming the introduction of the vector. In this case, the selectable marker gene may be the same as those listed above, but it must be different from the selectable marker genes for M1 and M2.

[0090] The DNA editing vector used in the DNA editing method of the present invention is a double-stranded, circular vector. Examples of such vectors include plasmid vectors, cosmid vectors, viral vectors, and artificial chromosome vectors. In addition to those consisting of DNA alone, vectors may also consist of RNA, GNA, LNA, BNA, PNA, TNA, and the like, or mixtures thereof. They may also be modified with components other than nucleic acids, such as sugars. The DNA editing vector used in the DNA editing method of the present invention can be prepared by known methods or methods similar thereto, as appropriate. For example, it can be obtained by artificial synthesis or by introducing the above-mentioned components into an existing vector.

[0091] (Introduction Step) In the DNA editing method of the present invention, the DNA editing vector and site-specific nuclease system are introduced into the cell and contacted with the target DNA. The site-specific nuclease system may be introduced into the cell in the form of a protein or RNA, in the form of DNA encoding the protein or RNA and expressed in the cell, or in the form of a vector (expression vector) that expresses the protein or RNA and expressed in the cell. Furthermore, when the site-specific nuclease system is a TALEN, the Left-TALEN and the Right-TALEN may be introduced together or separately, and when there are multiple TALENs, they may be introduced together or separately. Furthermore, when the site-specific nuclease system is a CRISPR-Cas system, the Cas protein and the guide RNA may be introduced together or separately, and when there are multiple CRISPR-Cas systems, they may be introduced together or separately. Among these, it is preferable to introduce it in the form of a vector that expresses a site-specific nuclease system (nuclease system expression vector) and express it in cells, as this can be easily introduced together with the DNA editing vector.

[0092] Such a nuclease system expression vector is not particularly limited, but preferably contains CEN / ARS as an autonomously replicating sequence from the viewpoint of being shed from the cell. Examples of such vectors include the ARS+all-in-one vector described in Non-Patent Document 3. More specifically, in the present invention, examples include nuclease system expression vectors containing: CEN / ARS, which is an autonomously replicating sequence; a second promoter P2; and a nucleotide sequence Nuc encoding the site-specific nuclease system operably linked to the second promoter P2. CEN / ARS is as described above. The second promoter P2 and other control sequences are not particularly limited, but include those similar to those listed above for the first promoter P1, and P1 and P2 may be the same. Here, "operably linked" between Nuc and P2 means that the second promoter P2 and Nuc are linked so as to enable expression of the site-specific nuclease system encoded by Nuc, and P2 is typically positioned upstream of Nuc. In addition, when there are multiple independent nucleotide sequences as Nuc (for example, a TALEN including a nucleotide sequence encoding a Left-TALEN and a nucleotide sequence encoding a Right-TALEN as described below), there may be multiple P2s corresponding to each nucleotide sequence, and the multiple P2s may be the same or different from each other.

[0093] Nuc is a nucleotide sequence encoding the site-specific nuclease system, and if the site-specific nuclease system is a TALEN, examples of such a nucleotide sequence include a combination of a nucleotide sequence encoding a fusion protein of a DNA-binding domain and a nuclease domain as a Left-TALEN, and a nucleotide sequence encoding a fusion protein of a DNA-binding domain and a nuclease domain as a Right-TALEN, and these may be on different vectors but are preferably on the same vector. Furthermore, when there are multiple TALENs, they may be on different vectors but are preferably on the same vector.

[0094] In the case of a CRISPR-Cas system, Nuc can be a combination of a nucleotide sequence encoding a Cas protein and a nucleotide sequence encoding its guide RNA, and these may be on separate vectors but are preferably on the same vector.Furthermore, when there are multiple CRISPR-Cas systems, they may be on separate vectors but are preferably on the same vector.

[0095] As described above, the nucleotide sequences encoding the nuclease domain (FokI) and the Cas protein are publicly known, and the nucleotide sequences encoding the DNA-binding domain and the guide RNA can be designed appropriately depending on the sequence near the target site of the target DNA, etc.

[0096] The nuclease system expression vector may further contain other regulatory elements (e.g., a terminator, an inducible promoter, a transcriptional regulator expression cassette, a transcriptional regulator binding sequence), etc., as appropriate, and may further contain a nucleotide sequence encoding a selectable marker gene for confirming the introduction of the vector. Examples of the selectable marker gene include those listed for the DNA editing vectors in the DNA editing method of the present invention, but they must be different from the selectable marker genes for M1 and M2 of the DNA editing vectors. Furthermore, when the DNA editing vector further contains a nucleotide sequence encoding a selectable marker gene other than the selectable marker genes for M1 and M2, the nucleotide sequence may be the same as, but preferably different from, this selectable marker gene, as needed. Such a nuclease system expression vector can be prepared by known methods or methods similar thereto, and can be obtained, for example, by artificial synthesis or by introducing the above-mentioned components into an existing vector.

[0097] Furthermore, in order to further improve DNA editing efficiency, it is preferable to introduce the DNA editing vector and the nuclease system expression vector into cells in the form of an integrated vector (integrated NICS vector) in which the DNA editing vector and the nuclease system expression vector are integrated. Examples of such integrated vectors include an integrated vector comprising: a first promoter P1; structure (1); a second promoter P2; and a nucleotide sequence Nuc encoding the site-specific nuclease system operably linked to the second promoter P2. Preferably, the integrated vector further comprises an autonomously replicating sequence, CEN / ARS. A preferred embodiment of the integrated vector configuration of the present invention is shown in Figure 3. CEN / ARS, P1, structure (1), P2, and Nuc operably linked to P2 are as described above. Furthermore, when T1 and T2, or G1 and G2, are designed to correspond to each site-specific nuclease system, they are similar to the DNA editing vectors described above.

[0098] The integrated vector may further include other regulatory elements (e.g., terminators, enhancers, insulators, transcriptional regulatory factor expression cassettes, transcriptional regulatory factor binding sequences), etc., as appropriate, similar to the DNA editing vectors described above, and may further include a nucleotide sequence encoding a selection marker gene for confirming the introduction of the vector. The selection marker gene may be the same as those listed above, but it must be different from the selection marker genes for M1 and M2. Such an integrated vector can be prepared by a known method or a method similar thereto, and can be obtained, for example, by artificial synthesis or by introducing the above-mentioned components into an existing vector.

[0099] The DNA editing vector (including the integrated vector) and the site-specific nuclease system can be introduced into the cells by various known methods, such as the polyethylene glycol method, electroporation, Agrobacterium-mediated methods, particle gun methods, laser ablation methods, and whisker methods.

[0100] (Cleavage step) In the DNA editing method of the present invention, in the introduction step, the DNA editing vector and the site-specific nuclease system are introduced into a cell and brought into contact with target DNA, whereby the site-specific nuclease system generates from the vector a fragment represented by the following structure (2): 5'-Hv1-D-Hv2-3' ... (2) and a fragment represented by the following structure (3): 5'-M2-P1-M1-3' ... (3) (if the vector further contains CEN / ARS, 5'-M2-CEN / ARS-P1-M1-3' ... (3)), and can cleave the target site or its vicinity in the target DNA.

[0101] Structure (2) contains Hv1, D, and Hv2 in this order from the 5' side, and the configuration of these is as described for structure (1). Structure (3) is the remaining structure obtained when structure (2) is excised from the DNA editing vector, and contains M2, P1, and M1 in this order from the 5' side, preferably M2, CEN / ARS, P1, and M1 in this order. Each component of structure (3) is as described for the DNA editing vector, and may further contain other components as appropriate. Furthermore, the cleavage sites in the DNA editing vector and the target DNA are as described above.

[0102] For example, cleavage within S1 and S2 by a TALEN may leave portions of T1 and T2 attached to the 5'-end of Hv1 and the 3'-end of Hv2 in structure (2), respectively, but these are typically removed by an intracellular repair system in the intracellular homology-dependent binding of Hv1 and Hv2 to Ht1 and Ht2. Cleavage within S1 and S2 by a TALEN may leave portions of T1 and T2 attached to the 3'-end of M1 and the 5'-end of M2 in structure (3), respectively, but these are typically removed by an intracellular repair system or the binding of M1 and M2 in cells (preferably, binding dependent on complementarity via the overlapping sequences). Similarly, when G1 and G2 are cleaved by the CRISPR-Cas system, even if some bases remain added to each end, they are usually removed by an intracellular repair system or the like during cleavage and / or binding, as in the case of cleavage by a TALEN.

[0103] (Editing step) The target DNA cleaved at or near the target site in the cleavage step and the fragment shown in structure (2) excised from the DNA editing vector bind depending on the homology between Ht1 and Hv1, and also bind depending on the homology between Ht2 and Hv2. In the context of Ht1 and Hv1, and Ht2 and Hv2, "homology-dependent binding" refers to binding by homologous sequence-dependent repair (HDR), in which each homologous sequence is aligned according to its sequence and undergoes annealing and ligation by the intracellular repair system, as well as removal of overhanging ends. This allows for the production of DNA-edited cells in which the desired nucleotide sequence D is accurately inserted into the target site, i.e., between Ht1 and Ht2, or in which the target site has been removed from between Ht1 and Ht2.

[0104] The presence or absence of insertion of the desired nucleotide sequence D or the presence or absence of removal of the target site can be confirmed based on conventionally known techniques, such as PCR, sequencing, Southern blotting, etc., which can be used as appropriate, and the DNA editing method of the present invention may further include a confirmation step using these.

[0105] (Selection step) In the fragment represented by structure (3) produced by cutting out the fragment represented by structure (2) in the cleavage step, M1 and M2 are functionally separated, so that the 3' end of M1 and the 5' end of M2 are joined to obtain a selection vector containing P1 and a functional selection marker gene operably linked to P1, preferably a selection vector containing CEN / ARS, P1, and a functional selection marker gene operably linked to P1. When the integrated vector is used as the DNA editing vector, a selection vector containing P1, a functional selection marker gene operably linked to P1, and a functional selection marker gene, P2, and Nuc operably linked to P2, preferably a selection vector containing CEN / ARS, P1, and a functional selection marker gene, P2, and Nuc operably linked to P2 is obtained.

[0106] Since the selectable marker gene functions in cells into which the selectable vector has been obtained, the cells can be selected and obtained using the selectable marker gene as an indicator. For example, if the selectable marker gene is a drug resistance gene, survival in an environment containing the drug can be used as an indicator for selection, and if the selectable marker gene is a reporter gene, its reporter activity (e.g., fluorescence) can be used as an indicator for selection.

[0107] Furthermore, since the fact that the selection vector has been obtained means that it is highly likely that the above-mentioned cutting and editing processes have also been carried out within the same cell, cells selected using the selection marker gene as an indicator can be selected as cells that are highly likely to have the desired nucleotide sequence D inserted into the target site or the target site removed, and DNA-edited cells in which the nucleotide sequence D has been inserted into the target site or the target site has been removed can be obtained with high efficiency.

[0108] (Removal of selection vector) The DNA-edited cells obtained by the DNA editing method of the present invention also contain the selection vector, and if this has CEN / ARS, it can be eliminated from the cells by culturing the cells, which is preferable. In addition, when an expression vector is used to introduce the nuclease system, for example, if the vector has CEN / ARS, such as the above-mentioned nuclease system expression vector, it can be eliminated from the cells in the same way.

[0109] For example, if the selection marker gene is a drug resistance gene, the above selection process is carried out under conditions (selective medium) in which the corresponding drug is added and selective pressure corresponding to the selection marker gene is applied, thereby obtaining DNA-edited cells in which the selection marker gene functions and the desired nucleotide sequence D is inserted into the target site or the target site is removed. Cells confirmed to have survived in the selective medium are then cultured under conditions without selective pressure, i.e., in a medium containing no drug, thereby eliminating the selection vector containing CEN / ARS. The culture period under the conditions without selective pressure is typically preferably 10 days or more, and more preferably 10 to 14 days. The loss of the selection vector from the cells can be confirmed, for example, by the inability of a portion of the strain cultured under the conditions without selective pressure to survive when transferred again to conditions with selective pressure (selective medium), or by the inability to detect a nucleotide sequence derived from the selection vector by PCR or the like.

[0110] Furthermore, for example, when the selection marker gene is a reporter gene, cells are selected using the confirmation of fluorescence or the like derived from the selection marker gene as an indicator up to the selection step described above, and DNA-edited cells are obtained in which the selection marker gene is functional and the desired nucleotide sequence D has been inserted into the target site or the target site has been removed. These cells are then typically cultured for 10 days or more, preferably 10 to 14 days, thereby shedding the selection vector or the like containing CEN / ARS, and cells in which the fluorescence or the like is no longer detected are obtained as cells from which the selection marker or the like has been shedding. Shedding of the selection vector or the like from the cells can also be confirmed, for example, by detecting the absence of a nucleotide sequence derived from the selection vector or the like by PCR or the like.

[0111] In the DNA editing method of the present invention, the introduction step, followed by the cleavage step, editing step, and selection step may occur in this order, or may occur simultaneously in parallel with one another. Hereinafter, referring to Figures 2A and 2B, a preferred embodiment of the DNA editing method of the present invention, up to the removal of the selection vector, will be described using an example of a method in which the nuclease system expression vector is used to introduce the site-specific nuclease system, but the present invention is not limited thereto.

[0112] In the DNA editing method of the present invention, the DNA editing vector and the nuclease system expression vector are first introduced into cells, whereupon the nuclease system (Nuc) is expressed from the nuclease system expression vector, cleaving the DNA editing vector and the target DNA (Figure 2A, left, three arrows: introduction step and cleavage step). This results in the insertion of the desired nucleotide sequence D into the target site or the removal of the target site (Figures 2A and 2B, where D is inserted into the target site), and cells containing the selection vector are obtained (Figure 2B, upper left: editing step and selection step). These cells can be selected using the selection marker gene contained in the selection vector. For example, if the selection marker gene is a drug resistance gene, cells into which only the DNA editing vector or the nuclease system expression vector has been introduced, or cells into which both have been introduced but cleavage has not occurred, cannot survive when cultured under selective pressure conditions with the addition of the corresponding drug (Figure 2A, right). This can be used as an indicator for selection and isolation. Furthermore, by culturing these cells (for example, if the selection marker gene is a drug resistance gene, culturing in a medium without the addition of the drug), the selection vector containing CEN / ARS and the nuclease system expression vector are eliminated (Figure 2B, right), and cells that do not contain any foreign genes other than the desired nucleotide sequence D can be obtained (Figure 2B, bottom left).

[0113] <Cell Production Method> The present invention provides a method for producing DNA-edited cells in which a desired nucleotide sequence has been inserted into a target site in target DNA or in which the target site has been removed, and the method includes the steps of: obtaining cells in which the desired nucleotide sequence D has been inserted into the target site or the target site has been removed by the DNA editing method of the present invention and which contain the selection vector; and selecting DNA-edited cells in which the desired nucleotide sequence D has been inserted into the target site or the target site has been removed, using a selection marker gene contained in the selection vector as an index.

[0114] The steps of obtaining cells in which the desired nucleotide sequence D has been inserted into the target site or the target site has been removed and which contain the selection vector by the DNA editing method of the present invention are as described above in the introduction step to the selection step. Furthermore, the step of selecting DNA-edited cells in which the desired nucleotide sequence D has been inserted into the target site or the target site has been removed, using a selection marker gene contained in the selection vector as an index, is also as described above in the selection step.

[0115] The cell production method of the present invention preferably further comprises the step of obtaining cells containing a selection vector containing CEN / ARS using a vector containing CEN / ARS as the DNA editing vector, and further culturing the DNA-edited cells to remove the selection vector from the cells. Such a step is as described in the removal of the selection vector. This makes it possible to obtain cells that do not contain any foreign genes other than the inserted desired nucleotide sequence.

[0116] Therefore, the present invention also provides a method for producing a non-human individual comprising cells in which a desired nucleotide sequence has been inserted into target DNA or in which the target site has been deleted, preferably a non-human individual comprising cells that do not contain any foreign genes other than the desired nucleotide sequence, which method comprises the step of producing a non-human individual from cells obtained by the above-mentioned cell production method of the present invention.

[0117] Non-human individuals include, for example, non-human animals, plants, and algae. Non-human animals include mammals (such as mice, rats, guinea pigs, hamsters, rabbits, humans, monkeys, pigs, cows, goats, and sheep), fish, birds, reptiles, amphibians, and insects. Plants include, for example, grains, oil crops, forage crops, fruits, and vegetables. Algae include Nannochloropsis, Chlamydomonas, Euglena, Chlorella, Botryococcus, diatoms, coccolithophorids, cyanobacteria, Cyanidioschyzon, Pseudococcomixa, Spirulina, and Haematococcus.

[0118] Known methods can be used as appropriate to create non-human individuals from cells. When creating non-human individuals from cells in animals, germ cells or pluripotent stem cells are usually used. For example, the DNA editing vector and site-specific nuclease system are microinjected into oocytes, and the resulting oocytes are then implanted into the uterus of a pseudopregnant female non-human mammal, followed by the production of offspring. Implantation can be performed using fertilized eggs at the 1-cell, 2-cell, 4-cell, 8-cell, 16-cell, or morula stage. Microinjected oocytes can be cultured under appropriate conditions until transplantation, if necessary. Oocyte transplantation and culture can be performed based on conventionally known techniques.

[0119] It has long been known that somatic cells of plants have totipotency, and methods for regenerating plants from plant cells have been established for various plants. Therefore, for example, by microinjecting the above-mentioned DNA editing vector and site-specific nuclease system into plant cells and regenerating plants from the resulting plant cells, a DNA-edited plant into which a desired nucleotide sequence has been inserted or in which the target site has been removed can be obtained.

[0120] The presence or absence of DNA editing can be confirmed based on conventionally known techniques, such as PCR, sequencing, Southern blotting, etc. From the obtained non-human individuals, it is also possible to obtain offspring or clones in which the desired DNA has been edited.

[0121] <DNA Editing Vector> The present invention provides a DNA editing vector for use in the DNA editing method of the present invention. The DNA editing vector of the present invention comprises: a first promoter P1; and the following structure (1'): 5'-M1-Hv1'-D'-Hv2'-M2-3' ... (1'), and the site-specific nuclease system generates a fragment represented by the following structure (2'): 5'-Hv1'-D'-Hv2'-3' ... (2') and a fragment represented by the following structure (3'): 5'-M2-P1-M1-3' ... (3'). The DNA editing vector of the present invention preferably further comprises the autonomously replicating sequence CEN / ARS, in which case a fragment represented by the structure (3') 5'-M2-CEN / ARS-P1-M1-3' is generated.

[0122] The DNA editing vector of the present invention is identical to the DNA editing vector for the DNA editing method of the present invention, including its preferred embodiments, except that in the above structure (1), D is replaced with the desired nucleotide sequence or its insertion site D' (although this may be absent in the case of the DNA removal method), and Hv1 and Hv2 are replaced with a nucleotide sequence homologous to the first nucleotide sequence Ht1 or its insertion site Hv1' and a nucleotide sequence homologous to the second nucleotide sequence Ht2 or its insertion site Hv2', respectively. In the DNA editing vector provided by the present invention, these configurations may be used as insertion sites so that users can design their own insertion sites according to their desired target sites. In this case, Hv1'-D'-Hv2' may be combined into a single insertion site. When Hv1', D', or Hv2' is the insertion site, structure (2') is a structure in which each component is inserted into structure (1') and then the structure is cleaved, i.e., 5'-Hv1-D-Hv2-3'...(2) (structure (2) is as described above).

[0123] Furthermore, when the site-specific nuclease system is a TALEN, the DNA editing vector of the present invention is the same as the DNA editing vector according to the DNA editing method of the present invention when the site-specific nuclease system is a TALEN, including its preferred embodiments, except that in the structure (11) above, in addition to the structure (1'), T1 and T2 are replaced with a TALEN_1 binding region or its insertion site T1' and a TALEN_2 binding region or its insertion site T2', respectively. Such a DNA editing vector may also have these configurations as its insertion site, allowing users to individually design it according to the desired target site. In this case, T1'-Hv1'-D'-Hv2'-T2' may be combined into a single insertion site.

[0124] Furthermore, when the site-specific nuclease system is a CRISPR-Cas system, the DNA editing vector of the present invention is the same as the DNA editing vector according to the DNA editing method of the present invention when the site-specific nuclease system is a CRISPR-Cas system, including its preferred embodiments, except that in the structure (12) above, in addition to the structure (1'), G1 and G2 are replaced with a first guide RNA recognition sequence or its complementary sequence or their insertion site G1', and a second guide RNA recognition sequence or its complementary sequence or their insertion site G2', respectively. Such a DNA editing vector may also have these configurations as its insertion site, allowing users to design their own target site. In this case, G1'-Hv1'-D'-Hv2'-G2' may be combined into a single insertion site.

[0125] An example of an insertion site in each of the above-mentioned structures is a multicloning site, but is not limited to this.

[0126] <DNA editing kit> The present invention also provides a kit for use in the DNA editing method of the present invention. The kit of the present invention comprises the DNA editing vector of the present invention and the site-specific nuclease system. The DNA editing vector and the site-specific nuclease system are as described above, including preferred embodiments thereof. Furthermore, the DNA editing vector and the site-specific nuclease system may be in the form of the integrated vector described above.

[0127] The DNA editing kit of the present invention may further include one or more reagents, such as, but not limited to, a drug or substrate corresponding to the selectable marker gene, a restriction enzyme and its reaction solution for inserting a target sequence into the insertion site, a dilution buffer, a reconstitution solution, a washing buffer, a control reagent (e.g., a control DNA-targeting nuclease system), and a reagent for introducing a vector into a cell.

[0128] Each component included in the DNA editing kit of the present invention may be contained in a separate container or may be contained in the same container. Furthermore, each component may be contained in a single-use amount, or multiple-use amounts may be contained in a single container (the user can simply take out the amount required for one use). Each component may be contained in a container in a dry form, or in a form dissolved in an appropriate solvent.

[0129] <Application of the NICS System> As described above, the DNA editing method of the present invention uses a site-specific nuclease system to cleave target DNA and excise a fragment (structure (2)) containing a nucleotide sequence homologous to the nucleotide sequences before and after the target site in the target DNA. This also produces a selection vector in which a selectable marker gene split into a 5' fragment M1 and a 3' fragment M2 binds and functions. Therefore, the presence of this selection vector makes it possible to efficiently obtain DNA-edited cells in which a desired nucleotide sequence has been inserted into the target site in the target DNA or in which the target site has been removed. The knowledge gained from the NICS system by the present inventors can be applied in other applications, such as a combination of two or more site-specific nuclease systems, each cleaving a different site, to perform multi-stage excision and ligation. Examples of such applications are shown in Figures 17 and 18 .

[0130] For example, when the site-specific nuclease system is a combination of two types of nuclease systems, nuclease system A (NucA) and nuclease system B (NucB), the configuration of the vector to be introduced into a cell can be exemplified as an application of the integrated vector according to the present invention, where the configuration is: Promoter Pa, the following structure (a): 5'-M1-Y-M2-3' ... (a), Promoter Pb, the following structure (b): 5'-Nb1-X-Nb2-3' ... (b), the following structure (c): 5'-Hv1-D-Hv2-3' ... (c). It is preferable that the integrated vector further comprises an autonomously replicating sequence CEN / ARS.

[0131] Here, in structure (a), M1 and M2 are the same as in structure (1) except that M1 is operably linked to promoter Pa (however, Pa is also synonymous with P1), and Y represents any nucleotide sequence. Furthermore, in structure (b), Nb1 represents the 5' fragment of the nucleotide sequence NucB encoding nuclease system B and is operably linked to promoter Pb (Pb is synonymous with P2), X represents any nucleotide sequence different from Y, and Nb2 represents the remaining 3' fragment of the nucleotide sequence encoding nuclease system B. Furthermore, structure (c) is synonymous with the above structure (2), but may be one type or two types. Furthermore, structure (c) is included in the vector as X and / or Y. When there is only one type of structure (c) and X or Y is other than structure (c), the nucleotide sequence of X or Y other than structure (c) is not particularly limited and may be any sequence, as long as it can disrupt the selectable marker gene or nuclease system B so that it does not function ( FIG. 17 ).

[0132] Similarly to M1 and M2 described above, Nb1 and Nb2 are nucleotide sequences in which nuclease system B (NucB) is disrupted so that the 3' end of Nb1 and the 5' end of Nb2 can bind and function. Therefore, nuclease system A (NucA, for example, the nuclease system expression vector described above) is designed to excise X from structure (b), and by introducing the vector and NucA into a cell, X is excised and the 3' end of Nb1 and the 5' end of Nb2 bind, allowing NucB to function. The functional NucB is further designed to excise Y from structure (a), whereby Y is excised and the 3' end of M1 and the 5' end of M2 bind, allowing the selection marker gene to function, and a selection vector similar to that described above containing the selection marker gene (and NucB) can be obtained. Structure (c), X and / or Y, are excised, and depending on the homology between Ht1 and Hv1 and between Ht2 and Hv2, either nucleotide sequence D is inserted into the target site of the target DNA (Figures 17-18) or the target site is removed from the target DNA (not shown), as in the NICS system described above. When structure (c) is one type, the site-specific nuclease system that cleaves the target DNA may be NucA or NucB. When structure (c) is two types, it is preferable that the nuclease that excises the structure and the nuclease that cleaves the site or surrounding area where the structure is inserted are the same (for example, in Figure 18, NucA excises X and cleaves the target site or surrounding area where X is inserted, while NucB excises Y and cleaves the target site or surrounding area where Y is inserted).

[0133] The present invention will be described in more detail below with reference to examples and comparative examples, but the present invention is not limited to the following examples. The following tests were carried out under the following conditions and methods.

[0134] 1. Target cells and their culture conditions 1 As one embodiment of the target cells, a Nannochloropsis strain (Nannochloropsis oceanica, National Institute for Environmental Studies, Microbial Culture Collection (NIES Collection), preservation number: NIES-2145), a unicellular alga, was used. The F2N liquid medium shown in 2. below was used as the culture medium. The cells were cultured in an LP-200P incubator (NK System) in an Erlenmeyer flask equipped with a filter at a temperature of 25°C and a light intensity of 57 μmol photons m -2 ・s -1 The culture was performed under conditions of 102 rpm and a shaking speed of 102 rpm. For normal plate culture, the F2N plates shown in 3. below were used. For culture with antibiotics added (culture on selective plates), F2N 50% seawater medium plates prepared in the same manner as the F2N plates shown in 3. below were used, except that the amount of Daigo Artificial Seawater SP in (B) was halved (18 g) and the antibiotics were added aseptically when (A) to (D) were mixed. The final concentrations of the antibiotics were 2 μg / mL for Zeocin and 150 μg / mL for Paromomycin.

[0135] 2. Preparation of F2N liquid medium F2N liquid medium was prepared by mixing the following (A), (B), and (C). The composition for preparing 1 L of F2N liquid medium is shown below.

[0136] (A) NaNO 3 (75mg / mL) 1mL NaH 2 P.O. 4 ・2H 2 O (30mg / mL) 1mL Na 2 SiO 3 ・9H 2 O (10mg / mL) 1mL f / 2 metal 5mL 1M Tris-HCl (pH 7.6) (12.11g / 100mL) 10mL 500mM NH 4 Cl (2.67 g / 100 mL) 10 mL The above composition was diluted to 500 mL with ultrapure water and sterilized in an autoclave.

[0137] The f / 2 metal used was prepared by mixing a solution having the following composition, diluting it to 100 mL with ultrapure water, sterilizing it in an autoclave, and storing it at 4°C.

[0138] Na 2 ・EDTA 440mg FeCl 3 ・6H 2 O 316mg CoSO 4 ・7H 2 O (1.2mg / mL) 1mL ZnSO 4 ・7H 2 O (2.1 mg / mL) 1 mL MnCl 2 ・4H 2 O (18mg / mL) 1mL CuSO 4 ・7H 2 O (0.7mg / mL) 1mL Na 2 MoO 4 ・7H 2 1 mL of O (0.7 mg / mL).

[0139] (B) Daigo Artificial Seawater SP (Fujifilm Wako Pure Chemical Industries, Ltd.) 36 g Diluted to 500 mL with ultrapure water and sterilized in an autoclave.

[0140] (C) Thiamine HCl (1 mg / mL) 500 μL Vitamin B12 (50 μg / mL) 50 μL Biotin (50 μL / mL) 50 μL Each was filter-sterilized and stored at −20° C., and then aseptically added to the autoclave-sterilized mixture of (A) and (B).

[0141] 3. Preparation of F2N Plates F2N plates (solid medium) were prepared by mixing the following (A), (B), (C), and (D), pouring the mixture into a 9 mm diameter plastic plate, and allowing it to air-cool and solidify. The composition for preparing 1 L of F2N solid medium is shown below.

[0142] (A) NaNO 3(75mg / mL) 1mL NaH 2 P.O. 4 ・2H 2 O (30mg / mL) 1mL Na 2 SiO 3 ・9H 2 O (10mg / mL) 1mL f / 2 metal 5mL 1M Tris-HCl (pH 7.6) (12.11g / 100mL) 10mL 500mM NH 4 The above composition was diluted to 250 mL with ultrapure water and sterilized in an autoclave. f / 2 metal is as shown in 2. above.

[0143] (B) Daigo Artificial Seawater SP (Fujifilm Wako Pure Chemical Industries, Ltd.) 36 g Diluted to 450 mL with ultrapure water and sterilized in an autoclave.

[0144] (C) Thiamine HCl (1 mg / mL) 500 μL Vitamin B12 (50 μg / mL) 50 μL Biotin (50 μL / mL) 50 μL Each was filter-sterilized and stored at −20°C, and then aseptically added to the autoclave-sterilized mixture of (A), (B), and (D).

[0145] (D) Agar 8 g was suspended in 300 mL of ultrapure water and sterilized in an autoclave.

[0146] 4. Nannochloropsis Cell Count Nannochloropsis culture medium was collected, and 2 μL was added to a bacteria counter counting chamber (SLGC) using a pipette. The number of cells was counted by observing with an ECLIPSE E100 microscope (Nikon Corporation). The count was performed twice, and the average value was calculated as the cell number.

[0147] 5. Electroporation Method For electroporation, the following conventional method (5-2) and new method (5-3) were used. Unlike the conventional method, method (5-3) does not require carrier DNA using salmon sperm DNA, which is an exogenous gene. Pre-culture (5-1) and plating (5-4) are common to both methods.

[0148] 5-1. Pre-culture: Cultivate Nannochloropsis strains under the normal culture conditions described in 1 above for 7 to 10 days until the cell concentration reaches 2.5 x 10 6 The cells were then subcultured in 250 mL of F2N liquid medium to a density of 1000 cells / mL, and further cultured.

[0149] 5-2. Electroporation using Gene Pulser Xcell (BIORAD) The cell concentration of Nannochloropsis strains cultured for 4 to 6 days after the pre-culture was measured using a cell count. 200 mL of culture medium was collected into four 50 mL Falcon tubes and centrifuged at 4°C and 4,900 rpm for 7 minutes. The supernatant was removed, and 37.5 mL of ice-cold 375 mM sorbitol was added to each tube, followed by suspending the cells. The cells were then centrifuged at 4°C and 4,900 rpm for 7 minutes, and the supernatant was removed. This procedure was repeated twice to wash the cells, and then the cells were resuspended at a final cell concentration of 1.5 x 10 9Cells were suspended in 375 mM sorbitol to a concentration of 1000 cells / mL. 3 μL of salmon sperm DNA (10 mg / mL) was used as carrier DNA and incubated at 95°C for 1 minute, then rapidly cooled on ice. The DNA to be introduced (each vector, knock-in fragment, etc.) was mixed with 3 μL of carrier DNA and placed in a Gene Pulser Cuvette 0.2 cm (BIORAD). 150 μL of the cell suspension was added and cooled on ice for 5 minutes or more. The cuvette was wiped dry, and electroporation was performed under the following conditions: Voltage: 2200 V, Capacitance: 50 μF, Resistance: 600 Ω, Cuvette length: 2 mm. After electroporation, the entire solution was transferred as quickly as possible to a 15 mL Falcon tube containing 5 mL of F2N liquid medium. The cap of the Falcon tube was loosened and fixed with surgical tape, and the tube was placed under low light conditions with shaking for recovery culture.

[0150] 5-3. Electroporation using ELEPO21 (Neppa Gene) As in 5-2 above, Nannochloropsis strains cultured for about 4 to 6 days after the pre-culture were harvested and washed twice, and the cell suspension was combined into two centrifuge tubes. The cells were then washed twice with 40 mL each of 375 mM sorbitol to remove salt from the medium. After that, the cells were washed twice with 40 mL each of 375 mM sorbitol to remove salt from the medium. 10Cells were suspended in ice-cold 375 mM sorbitol to a concentration of 1000 cells / mL. 2 μL (or 1 μL) of DNA to be introduced (total amount), 38 μL of cell suspension, and 40 μL of 375 mM sorbitol were suspended, and after leaving at room temperature for 10 minutes, the solution was transferred to a 1 mm gap cuvette and ice-cooled for 5 minutes or more. The ice-cooled cuvette was wiped dry, and the corner of the cuvette was gently tapped on the laboratory bench to remove air bubbles, after which it was placed in the chamber and electroporated. Electroporation was performed under the following conditions: Poring plus: Voltage: 1750 V, pulse width: 3.5 ms, pulse interval: 50 ms, number of times: 1, polarity: + Transfer plus: Voltage: 100 V, pulse width: 50 ms, pulse interval: 50 ms, number of times: 3, polarity: + / -. After electroporation, recovery culture was carried out in the same manner as in 5-2 above.

[0151] 5-4. Plating After 2-4 days of recovery culture, the paper towels and tape were removed from the 15 mL Falcon tube in which the recovery culture had been performed, and the tube was centrifuged at 2,000 rpm for 5 minutes, and the supernatant was removed. The cells were suspended in 2 mL of Top Agar that had been heated and melted in a microwave oven and cooled to approximately 40°C, and then applied to an F2N 50% seawater medium plate containing an antibiotic appropriate for the introduced DNA. The plate was then dried for approximately 30 minutes to solidify the agar. The plate was sealed with surgical tape and subjected to static culture in an incubator to form colonies. F2N liquid medium containing 0.4% agar was used as the Top Agar.

[0152] 6. Extraction of Genomic DNA Genomic DNA was extracted from cells (Nannochloropsis) using the following method 6-1 or 6-2.

[0153] 6-1. Method using phenol / chloroform First, cells were cultured in 2 mL of F2N liquid medium in a 12-well plate for approximately two weeks, and the culture medium was centrifuged at 20°C and 4,900 rpm for 5 minutes to recover the cells. 500 μL of TEN buffer was added to suspend the pellet, and the mixture was centrifuged at 20°C and 4,900 rpm for 5 minutes, and the supernatant was removed with a pipette. The pellet was suspended in 150 μL of ice-cold sterile ultrapure water, and immediately after that, 350 μL of SDS-EB buffer was added and mixed. 500 μL of a 1:1 phenol / chloroform solution was added, mixed vigorously, and centrifuged at room temperature at 14,500 rpm for 10 minutes. The upper layer was transferred to a new 1.5 mL tube, and 500 μL of phenol / chloroform solution was added again, mixed, and centrifuged at room temperature at 14,500 rpm for 10 minutes. The upper layer was transferred to a new 1.5 mL tube, and 50 μL of 1.82 M NaCl and 500 μL of isopropanol were added and mixed slowly. The mixture was centrifuged at room temperature at 14,500 rpm for 15 minutes, and the supernatant was removed. The pellet was slowly suspended in 200 μL of TE buffer, and 20 μL of 1.82 M NaCl and 550 mL of 100% ethanol were added and mixed. The mixture was centrifuged at 20°C at 14,500 rpm for 15 minutes, and the supernatant was removed. 200 μL of 70% ethanol was added, and the mixture was centrifuged at room temperature at 14,500 rpm for 10 minutes. The supernatant was removed with a pipette and dried under reduced pressure for 10 minutes. Then, 40 μL of TE buffer was added, heated at 55°C for 10 minutes, air-cooled to room temperature, and then left to stand at 4°C overnight to dissolve the genomic DNA in the TE buffer. The concentration of the genomic DNA was measured and diluted with sterile water to 10 ng / μL to use as template DNA for PCR. (TEN buffer) 1 mL of 1 M Tris-HCl, 2 mL of 500 mM EDTA, 0.8766 g of NaCl. Diluted to 100 mL with ultrapure water and sterilized in an autoclave.(SDS-EB buffer) 1M Tris-HCl 10mL, 500mM EDTA 8mL, NaCl 2.3376g, SDS 2.0g. Made up to 100mL with ultrapure water and sterilized in an autoclave. (1.82M NaCl) NaCl 5.3g. Made up to 50mL with ultrapure water and sterilized in an autoclave. (TE buffer) 1M Tris-HCl (pH 8.0) 1mL, 0.5M EDTA (pH 8.0) 0.2mL. Made up to 100mL with ultrapure water and sterilized in an autoclave.

[0154] 6-2. Method using a simple DNA extraction kit A simple DNA extraction kit (Kaneka Simple DNA Extraction Kit Version 2 (Kaneka Corporation)) was used to extract genomic DNA when examining many samples simply. Specifically, cell colonies were suspended in 10 μL of Reagent A and incubated at 98°C for 8 minutes. After cooling to room temperature, 1.4 μL of Reagent B was added and the mixture was stirred by pipetting. The resulting crude extract was diluted 1 / 10 with sterile water to serve as template DNA for PCR.

[0155] 7. PCR reaction The PCR reaction was performed using a reaction solution with the following composition, and was scaled up as necessary. The PCR reaction was performed using a thermal cycler with the following reaction cycle: (Reaction solution) KOD FX Neo buffer (manufactured by TOYOBO) 5 μL 2 mM dNTPs 2 μL Sterile ultrapure water 0.4 μL 10 mM primer solution 0.4 μL each Template DNA 2 μL KOD FX Neo (manufactured by TOYOBO) 0.2 μL (Reaction cycle) 94 ° C 2 min ↓ 98 ° C 10 sec 68 ° C 1 min / kb (1 min per 1 kb of amplification product) 30 cycles ↓ 68 ° C 1 min / kb + 1 min 4 ° C ∞.

[0156] 8. Agarose Gel Electrophoresis 50x TAE was diluted with ultrapure water to prepare 1x TAE. 1g / 100mL or 3g / 100mL Agarose S (Nippon Gene Co., Ltd.) was added to 1x TAE, dissolved by heating in a microwave oven, and poured into a gel maker equipped with a comb to prepare a 1% or 3% agarose gel. When the band size of the DNA to be electrophoresed was 1kb or less, a 3% agarose gel was used. 6x loading buffer (New England Biolabs) was added to the electrophoresis sample, applied to the well, and electrophoresis was performed at 100V until the gel filled approximately 70%. 4µL of ethidium bromide was added to ion-exchanged water, and the gel was immersed in electrophoresis and shaken for approximately 30 minutes to stain it. The electrophoresis pattern was observed using a transilluminator. (50x TAE) Tris 48.4 g 0.5 M EDTA 20 mL Acetic acid 11.42 mL Dilute to 200 mL with ultrapure water.

[0157] 9. Sequencing First, a sequencing reaction mix was prepared with the following composition: 2 μL 5x Sequence Buffer (Thermo Fisher Scientific), 0.32 μL each of 10 mM primers, and 100 ng / kb template DNA. Sterile ultrapure water was added to make 9 μL. The prepared sequencing reaction mix was heated to 95°C for 5 minutes, rapidly cooled on ice for 5 minutes, and then 1 μL of Big Dye terminator (Thermo Fisher Scientific) was added. The following reaction was carried out using a thermal cycler: 96°C for 2 minutes, 96°C for 10 seconds, 50°C for 5 seconds, 60°C for 4 minutes, 30 cycles, and 4°C. The primers used were a primer designed based on the nucleotide sequence upstream of Nannochloropsis PDAT1 (SEQ ID NO: 26 showing the nucleotide sequence) and a primer designed based on the nucleotide sequence downstream of Nannochloropsis PDAT1 (SEQ ID NO: 27 showing the nucleotide sequence).

[0158] After the reaction was complete, 10 μL of the reaction product was mixed with 1 μL of 1.5 M sodium acetate (pH 5.0), 1 μL of 0.25 M EDTA (pH 8.0), and 40 μL of 100% ethanol, and then allowed to stand at room temperature for 15 minutes. After centrifugation at 14,500 rpm at 20°C for 15 minutes, the supernatant was removed. 100 μL of 70% ethanol was added, and the mixture was centrifuged at 14,500 rpm at 20°C for 15 minutes. The supernatant was then removed and the mixture was dried under reduced pressure for 10 minutes. 20 μL of HiDi formamide was added to the dried sample to dissolve the pellet, which was then heated to 95°C for 2 minutes and rapidly cooled on ice for 5 minutes. The samples were transferred to a sequencing plate, a plate sealing mat was placed on the plate, and sequencing was performed using a SeqStudio™ Genetic Analyzer (Thermo Fisher Scientific).

[0159] 10. Loss of CEN / ARS vector Colonies grown on the selection plate were collected on an F2N plate (without antibiotics) to prepare a master plate. The colonies were transferred from the master plate to 30 mL of F2N liquid medium and cultured for 1 to 2 weeks, and then 1 × 10 6 The culture was then diluted with F2N medium to 3,000 cells / mL and plated onto F2N plates. The colonies formed on the F2N plates were then plated onto F2N plates and antibiotic-containing F2N 50% seawater plates, and strains that did not grow on the antibiotic-containing plates were identified as strains that had lost the CEN / ARS vector.

[0160] 11. DNA Extraction from Agarose Gel The Wizard® SV Gel and PCR Clean-Up System (Promega) was used to extract DNA from the agarose gel described in 8. above. After electrophoresis described in 8. above, gel pieces containing the bands of interest were excised with a razor and collected using a WSE-5400 Printgraph Classic (ATTO). 100 μL of Membrane Binding Solution (Promega) was added per 100 mg of gel pieces, followed by an additional 100 μL. The mixture was heated to 55°C in a block incubator, and the gel pieces were completely dissolved before being added to a column. The column was centrifuged at 12,000 rpm at room temperature for 2 minutes, the flow-through was removed from the collection tube, and 750 μL of Membrane Wash Solution (Promega) was added. The column was then washed by centrifugation at 12,000 rpm at room temperature for 2 minutes. The column was then washed again with 500 μL of Membrane Wash Solution. The column was centrifuged at 12,000 rpm at room temperature for 2 minutes to remove the Membrane Wash Solution from the column. The column was then placed in a new 1.5 mL tube, and 30 μL of Nuclease-Free Water (Promega) was added. The column was then left to stand for 1 minute, and then centrifuged at 12,000 rpm at 20°C for 2 minutes to elute the sample. The concentration of the extracted DNA solution was measured using Nanodrop (manufactured by Thermo Fisher Scientific) and used as the template DNA for the sequence in 9 above.

[0161] 12. Target Cells and Their Culture Conditions 2: HEK293T (human embryonic kidney cells) were used as another form of target cells. The following cell experiments were performed in a clean bench, and before starting the work, the equipment to be used (electric pipetter, pipette, plate, etc.) was placed in the clean bench and subjected to UV treatment for at least 15 minutes.

[0162] 12-1. Preparation of complete medium 500 mL of DMEM (High Glucose) with L-Glutamine and Phenol Red was mixed with 5.5 mL of 10x Non-Essential Amino Acid (NEAA), 5.5 mL of Penicillin-Streptomycin (ST-PN), and 55 mL of Fetal Bovine Serum (FBS) inactivated at 56°C for 30 minutes, and stored at 4°C to prepare the complete medium described below.

[0163] 12-2. Culturing HEK293T The medium was removed from a 100 mm plate in which HEK293T was being cultured using an aspirator, and 10 mL of the complete medium prepared in 12-1 above was added. The cells were detached from the plate by pipetting with an electric pipetter, and the cell clumps were broken up to obtain a cell suspension. 10 mL of the cell suspension was added to a 100 mm plate that had already been filled with the complete medium. The plate was shaken to distribute the cells uniformly, and the cells were incubated at 37°C, 5% CO 2 This procedure was carried out every 2 to 3 days to prevent the cells from overgrowing in the plate.

[0164] 12-3. Introduction of Vectors into Cultured Cells (Lipofection) First, using each vector solution prepared at 200 ng or 100 ng / μL, the vector was mixed as needed and prepared with sterile ultrapure water so that the total concentration of the vector to be introduced was 100 ng / 6 μL or 200 ng / 6 μL. 25 μL of D-MEM was added to each well of a 96-well plate, followed by 6 μL of the prepared vector. Furthermore, a mixture of 25 μL of D-MEM and 0.7 μL of Lipofectamine LTX (Thermo Fisher Scientific) in a 1.5 mL tube was added to each well and allowed to stand at room temperature for 30 minutes.

[0165] Additionally, from a 100 mm plate in which HEK293T cells were cultured in complete medium, the medium was removed using an aspirator, and 3 mL of TrypLE™ Express was added and incubated for 30 seconds. 7 mL of complete medium was added, and the cells were suspended using an electric pipettor. The entire volume was transferred to a 50 mL tube. The mixture was centrifuged at 20°C and 1000 rpm for 3 minutes, the supernatant was removed using an aspirator, and the cells were resuspended in 3 mL of complete medium. The cell number was counted using a Luna automated cell counter (Logos Biosystems), and a cell count of 1.0 x 10 4 The diluted cell suspension was added to each well in an amount of 100 μL at 37°C, 5% CO 2 The cells were cultured for 24 hours under the conditions.

[0166] 12-4. Selection of vector-introduced cells using antibiotics After 24 hours of culture as described in 12-3 above, cells transfected with the GFP expression vector (pMAX_GFP) were observed under a microscope to confirm that lipofection had been performed, and then cell selection was performed. First, the medium during culture in the 96-well plate was removed using an aspirator, and 150 μL of complete medium containing an antibiotic (puromycin) adjusted to a concentration of 0 to 20 μg / mL was added to each well. The plates were then incubated at 37°C, 5% CO 2 The cells were cultured for 48 hours under the conditions. After culture (72 hours after lipofection), the cells were collected and cell counted according to the method described in 12-5 below. The medium was not changed during the 48 hours between the addition of the antibiotic and the collection of the cells.

[0167] 12-5. HEK293T Cell Count: Before harvesting the cells, cells transfected with pMAX_GFP were observed under a microscope to confirm that pMAX_GFP expression was reduced in an antibiotic (puromycin) concentration-dependent manner. Next, the culture medium from the 96-well plate was transferred to a separate PCR tube, and 50 μL of TrypLE Express (Thermo Fisher Scientific) was added to each well and incubated at 37°C for 5 minutes. After transferring the cells to the PCR tube, the cells were suspended in the medium using a multipipette, and the suspension was then recovered again in the PCR tube. Next, 10 μL of the cell suspension collected in the PCR tube was removed, and the number of cells was counted using a Luna automated cell counter (Logos Biosystems). Viability (viability: number of cells after 48 hours of culture in 12-4 (after antibiotic addition) / number of cells after 24 hours of culture in 12-3 (before antibiotic addition) × 100 [%]) was calculated.

[0168] 13. Genotyping 13-1. Genome Extraction and Purification After 12-4 above, the cell suspension collected in 12-5 was centrifuged at 13,000 rpm for 3 minutes, and the medium (supernatant) was removed. Next, 150 μL of PBS(-) was added, and the mixture was centrifuged at 13,000 rpm for 3 minutes to remove the supernatant. 150 μL of PBS(-) was added, and the mixture was centrifuged again at 13,000 rpm for 3 minutes to remove the supernatant. A mixture of 20 μL of lysis buffer and 0.8 μL of protein degrader was added to each PCR tube, and the mixture was incubated at 68°C for 15 minutes, then at 95°C for 10 minutes, and stored at 4°C. It was then transferred to -20°C and used as the PCR template described below.

[0169] 13-2. PCR Amplification of Insertion Sequence After genome extraction as described in 13-1 above, to confirm whether the desired knock-in fragment (3xFlag sequence) was inserted into the target locus, forward and reverse primers were designed outside the nucleotide sequences (Ht1, Ht2) at both ends of the target site, and out-out PCR was performed. Primers were designed based on the nucleotide sequences encoding each target gene and its surroundings using Primer 3plus (https: / / www.primer3plus.com) and NCBI BLAST (https: / / blast.ncbi.nlm.nih.gov / Blast.cgi?PROGRAM=blastn&PAGE_TYPE=BlastSearch&LINK_LOC=blasthome). As PCR enzymes, PrimeSTAR MAX DNA Polymerase (manufactured by Takara Bio Inc.) was used for ATP5B, and PrimeSTAR GXL DNA Polymerase (manufactured by Takara Bio Inc.) was used for PARP1.

[0170] [Method using PrimeSTAR MAX DNA Polymerase] 0.2 μL of the PCR template prepared in Section 13-1 above, 5.0 μL of 2x PrimeSTAR MAX Premix (Takara Bio Inc.), 0.3 μL of 10 μM forward primer, 0.3 μL of 10 μM reverse primer, and 4.2 μL of sterile ultrapure water were mixed. Using a thermal cycler, the mixture was preheated at 94°C for 2 minutes, followed by 35 to 40 cycles of thermal denaturation at 98°C for 10 seconds, annealing at 66°C for 5 seconds, and extension at 72°C for 5 seconds, and then stored at 4°C. The PCR product was subjected to agarose gel electrophoresis using the method in Section 8 above, and a band of the desired length containing the knock-in sequence was confirmed.

[0171] [Method using PrimeSTAR GXL DNA Polymerase] 1.25 μL of the PCR template prepared in 13-1 above, 0.5 μL of PrimeSTAR GXL DNA Polymerase (manufactured by Takara Bio Inc.), 5.0 μL of 5× PrimeSTAR GXL Buffer (manufactured by Takara Bio Inc.), 2.0 μL of 2.5 mM each dNTP mixture, 0.75 μL of 10 μM forward primer, 0.75 μL of 10 μM reverse primer, and 14.75 μL of sterilized ultrapure water were mixed. Using a thermal cycler, the mixture was preheated at 94°C for 2 minutes, followed by 40 cycles of heat denaturation at 98°C for 10 seconds, annealing at 70°C for 15 seconds, and extension at 68°C for 5 seconds, and then stored at 4°C. The PCR product was subjected to agarose gel electrophoresis as described in 8 above, and a band of the desired length containing the knock-in sequence was confirmed.

[0172] 14. TIDER Analysis As a reference for TIDER (Tracking of Insertion, Deletions, and Recombination events) analysis, a TA vector was prepared into which a desired knock-in fragment (3x Flag sequence) containing homologous sequences (Hv1, Hv2) was inserted.

[0173] 14-1. TA Cloning 9 μL of the PCR product from 13-2 above was mixed with 1 μL of 10x A-attachment mix (TArget Clone -Plus-, TOYOBO) and incubated for 30 minutes at 60 ° C using a thermal cycler. 3 μL of the incubated solution was mixed with 5 μL of 2x Ligation Buffer (TArget Clone -Plus-, TOYOBO), 1 μL of 50 ng / μL pTA2 vector (TArget Clone -Plus-, TOYOBO), and 1 μL of T4 DNA Ligase (TArget Clone -Plus-, TOYOBO) in a PCR tube. After incubating at 16°C for 30 minutes using a thermal cycler, 3 μL of this reaction solution was mixed with 30 μL of XL10-Gold (Agilent) and left to stand on ice for 10 minutes. After incubating at 42°C for 30 seconds using an incubator, the mixture was left to stand on ice for at least 2 minutes. This mixture was spread on an LB+Amp plate whose surface had been coated with a mixture of 20 μL of 5% X-gal, 10 μL of 0.1 M IPTG, and 70 μL of SOC. After incubating at 37°C for approximately 16 hours, white colonies that could no longer decompose X-gal were picked, and vector introduction was confirmed by colony PCR. Colonies in which vector introduction was confirmed were small cultured, and each plasmid (TA cloning vector) was extracted by miniprep.

[0174] 14-2. Sequencing, TIDER analysis Using the TA cloning vector obtained in 14-1 above as a template, sequence analysis was performed using vector primers according to the method in 9 above, and HDR efficiency (HDR efficiency [%]) was determined using TIDER (https: / / tide.nki.nl / ) with the following parameter settings: Alignment Window (bp): 69, Decomposition Window (bp): 70-94, Indel size range: 5 (for PARP1).

[0175] <Test Example 1> Insertion of knock-in fragment (Comparative Example) First, the method shown in Figure 4 was designed, and upstream of LPAT1, which is a membrane lipid synthesis-related gene (target DNA) of the target cell Nannochloropsis, was added a homologous sequence (homology arm) to the LDSP promoter (ProLDSP) and the nucleotide sequence of the desired target site upstream of LPAT1. It was attempted to insert a knock-in fragment (nucleotide fragment) by adding. In the method shown in Figure 4, the knock-in fragment containing the LDSP promoter (ProLDSP) is inserted upstream of LPAT1, while the CEN / ARS vector, all-in-one PtTALEN-ARS vector, is not inserted into the target DNA (target DNA), which is genomic DNA. Therefore, after the desired insertion is achieved, it is thought that by performing the removal of the CEN / ARS vector, it becomes possible to insert DNA without leaving any foreign genes other than the knock-in fragment in the cell.

[0176] The knock-in fragment used was a knock-in fragment (total 1304 bp, approximately 790 ng) consisting of the nucleotide sequence shown in SEQ ID NO: 20, in which a sequence identical to the 217 bases preceding the start codon of Nannochloropsis LPAT1 (SEQ ID NO: 21) was added to the 5' side of the sequence encoding Nannochloropsis ProLDSP, and a sequence identical to the 320 bases following the start codon of LPAT1 was added to the 3' side. However, in the nucleotide sequence shown in SEQ ID NO: 20, a partial mutation was introduced into the sequence corresponding to the DNA-binding domain recognition sequence of the R-TALEN of PtTALEN described below, so that the knock-in fragment would not be cleaved by the TALEN.

[0177] Furthermore, an all-in-one PtTALEN-ARS vector (520 ng) was prepared in which the amino acid sequence of the PtTALEN DNA binding domain in the all-in-one PtTALEN-ARS plasmid described in Non-Patent Document 3 was designed to cleave between bases 111 and 125 from the start codon of LPAT1 of Nannochloropsis.

[0178] The knock-in fragment and the all-in-one PtTALEN-ARS vector were electroporated into Nannochloropsis cells using the method described in 5-3. The all-in-one PtTALEN-ARS vector contained a zeocin-resistant gene (ShBle) to form colonies on a zeocin-containing F2N 50% seawater medium plate (selection plate). Genomic DNA was extracted from each colony (12 colonies) using the method described in 6-1. PCR reactions were performed using a combination of primers designed within the knock-in fragment (ProLDSP) and on the target DNA (upstream and downstream of LPAT1), as shown in Figure 5(a), using the method described in 7. above. The nucleotide sequences of the primers are shown in SEQ ID NOs: 22 to 25 in the order of forward primer for out-out PCR (forward primer for 5' junction PCR), reverse primer (reverse primer for 3' junction PCR), reverse primer for 5' junction PCR, and forward primer for 3' junction PCR.

[0179] The amplified products after the PCR reaction were subjected to agarose gel electrophoresis using the method described in 8 above, and the results are shown in Figure 5(b). As shown in Figure 5(a), if the desired insertion is achieved, bands of 3151 bp, 1369 bp, and 1517 bp are all confirmed. However, no bands of this combination were confirmed in any of the colonies, confirming that the method shown in Figure 4 does not provide sufficient DNA insertion efficiency.

[0180] <Test Example 2> Construction of a non-integration cleavage-dependent selection (NICS) vector One of the reasons for the low DNA insertion efficiency in Test Example 1 was that few colonies formed on the selection plate were simultaneously introduced with the knock-in fragment and the all-in-one PtTALEN-ARS vector, and a new method was designed as shown in Figure 1A. In the method shown in Figure 1A, the selection marker gene (in this test example, the paromomycin resistance gene) is divided into the 5' side (M1) and the 3' side (M2), and between them, homologous sequences (Hv1, Hv2) to the nucleotide sequences at both ends of the target site and the target DNA (D, in this test example, the LDSP promoter) were inserted as knock-in fragments so that they could be removed by a site-specific nuclease system (TALEN in this test example) A vector was constructed (Figure 1A (a)). This vector is cleaved in cells into which the site-specific nuclease system has been introduced, i.e., cells in which it is highly likely that the target DNA has also been cleaved and the knock-in fragment has been inserted (Figure 1A (c)), and the remaining fragment binds to allow the selection marker gene to function (Figure 1A (b)), thus improving DNA insertion efficiency. In this test example, the target site selected was the upstream site of PDAT1, a Nannochloropsis gene that synthesizes oils by transferring an acyl group to diacylglycerol and whose overexpression in other algae has been reported to increase oils.

[0181] (1) Verification Test 1 First, to confirm that this system functions in Nannochloropsis, a verification vector was prepared and confirmed. First, in a vector containing CEN / ARS (nucleotide sequence shown in SEQ ID NO: 1), a paromomycin resistance gene (aphVIII), and a Nannochloropsis promoter (ProLHC, nucleotide sequence shown in SEQ ID NO: 2) and terminator (terFCP, nucleotide sequence shown in SEQ ID NO: 9) for the paromomycin resistance gene, the paromomycin resistance gene (aphVIII) was divided into a 5' fragment (aphVIII-5', nucleotide sequence shown in SEQ ID NO: 3) and a 3' fragment (aphVIII-3', nucleotide sequence shown in SEQ ID NO: 8) with a 207-bp overlap sequence (pMD20-ARS-aphVIII-sep-BamHI, FIG. 6A). Next, the binding region of PtTALEN for nitrate reductase NoNR (Kurita et al., Genes Cells., 2020; 00: pp. 1-8, DOI: 10.1111 / gtc.12805 (Reference I)) was inserted between these fragments to create a validation vector, NoNR. A conceptual diagram of the constructed validation vector, NoNR, is shown in Figure 6B (a). When this vector is cleaved by the NoNR PtTALEN, the paromomycin resistance gene functions, and paromomycin-resistant colonies are formed on the selection plate (Figure 6B (b)).

[0182] Furthermore, in the all-in-one PtTALEN-ARS plasmid described in Non-Patent Document 3, an all-in-one PtTALEN vector (TALEN vector_NoNR) was prepared in which the amino acid sequence of the DNA binding domain of PtTALEN was changed to a sequence that binds to the binding region of the PtTALEN for NoNR, and an all-in-one PtTALEN vector (TALEN vector_LPAT1) was prepared in which the amino acid sequence of the DNA binding domain of PtTALEN was changed to a sequence that binds to the binding region of PtTALEN near the target site of LPAT1 (Reference I).

[0183] Tests were performed using only the verification vector NoNR (No. 2), a combination of the verification vector NoNR and the TALEN vector NoNR (No. 3), and a combination of the verification vector NoNR and the TALEN vector LPAT1 (No. 4). Tests were also performed using the pMD20-ARS-aphVIII-sep-BamHI vector (a control vector in which a BamHI site has been inserted between the 5' and 3' fragments of the paromomycin resistance gene in place of the PtTALEN binding region, so that the 5' and 3' fragments are bound in frame) (No. 1). 200 ng of each vector was used and transfected into Nannochloropsis cells as described in 5-3. Electroporation was performed according to the method described above, and the number of paromomycin-resistant colonies formed on F2N 50% seawater medium plates containing paromomycin was counted. The results are shown in Figure 7A. Genomic DNA was extracted from representative colonies of each vector combination according to the method described in 6-1. PCR was performed according to the method described in 7. above using combinations of primers designed on the 5' and 3' fragments shown in Figure 7B(a). The amplified products after PCR were subjected to agarose gel electrophoresis according to the method described in 8. above, and the results are shown in Figure 7B(b).

[0184] As shown in Figure 7A, paromomycin-resistant colonies were sufficiently formed in cells transfected with the combination of the verification vector NoNR and the TALEN vector NoNR (No. 3). Furthermore, as shown in Figure 7B (a), a 529 bp band was observed in cells transfected with a control vector in which the 5' and 3' fragments of the paromomycin resistance gene were linked in frame. A 558 bp band was observed in cells in which the verification vector NoNR was not cleaved by PtTALEN. A 301 bp band was observed in cells in which the verification vector NoNR was cleaved by PtTALEN and recombined via the overlapping sequence. As shown in Figure 7B (b), a 301-bp band was observed in the combination of the verification vector NoNR and the TALEN vector NoNR (No. 3), confirming that the verification vector NoNR was cleaved by PtTALEN and bound via the overlapping sequence, and that the paromomycin resistance was due to the paromomycin resistance gene after ligation. However, as shown in Figure 7A, many paromomycin-resistant colonies were formed even in cells transfected with the control vector (No. 1), in which the 5' and 3' fragments of the paromomycin resistance gene were linked in frame.

[0185] (2) Verification Test 2 As described in (1) above, even when the 5'- and 3'-fragments of the paromomycin resistance gene recombine in frame, many paromomycin-resistant colonies are formed as background. Therefore, vectors (verification vector_NoNR_stop, control vector_stop) in which a stop codon (TAG) is inserted immediately after the 5'-fragment of the paromomycin resistance gene were prepared, and a test similar to that in (1) was performed. In addition, a vector (verification vector_LPAT1_stop) in which the binding region of the PtTALEN for LPAT1 was inserted instead of the binding region of the PtTALEN for NoNR between the 5'- and 3'-fragments of the paromomycin resistance gene was also prepared in the same manner. Control vector_stop only (No. 1), verification vector_NoNR_stop only (No. 2), verification vector_NoNR_stop and TALEN vector_NoNR were also prepared. The following combinations were performed: a combination of NoNR and TALEN vector LPAT1 (No. 3), a combination of NoNR and TALEN vector LPAT1 (No. 4), a combination of LPAT1 only (No. 5), a combination of LPAT1 and TALEN vector LPAT1 (No. 6), and a combination of LPAT1 and TALEN vector LPAT1 (No. 7). The results are shown in Figure 8.

[0186] As shown in Figure 8, in cells transfected with a combination of the verification vector NoNR_stop and the TALEN vector NoNR (No. 3) and a combination of the verification vector LPAT1_stop and the TALEN vector LPAT1 (No. 6), paromomycin-resistant colonies were sufficiently formed, as in (1) above. On the other hand, in the strain transfected with the control vector stop (No. 1), the amount of paromomycin-resistant colonies formed was reduced compared to (1) above, and the background was successfully reduced sufficiently.

[0187] (3) Construction of NICS Vector (Example) Based on the verification results of (1) and (2) above, a vector (NICS vector) to be used in the method shown in Figure 1A was constructed using pMD20-ARS-aphVIII-sep-BamHI shown in Figure 6A. A conceptual diagram showing more specifically the structure of the vector constructed as the NICS vector shown in Figure 1A(a) and Figure 1C(a) is shown on the left side of Figure 9(a). The NICS vector shown on the left side of Figure 9 (a) has the following configuration: CEN / ARS (SEQ ID NO: 1), a promoter P1 (ProLHC, SEQ ID NO: 2) and terminator (terFCP, SEQ ID NO: 9) for the paromomycin resistance gene, a sequence in which the paromomycin resistance gene (aphVIII) is divided into a 5' fragment M1 (aphVIII-5', SEQ ID NO: 3) and a 3' fragment M2 (aphVIII-3', SEQ ID NO: 8) with a 207 bp overlapping sequence between the promoter and the terminator, and binding regions T1 and T2 of PtTALEN for PDAT1 (both SEQ ID NO: 4, 5'-L1 (Left-TALEN DNA binding domain recognition sequence, SEQ ID NO: 10)-S1 (spacer sequence)-R1 (Right-TALEN The complementary sequence of the DNA-binding domain recognition sequence, SEQ ID NO: 11)-3'), homologous sequences Hv1 and Hv2 were inserted between T1 and T2, and ProLDSP (SEQ ID NO: 6) was included as knock-in fragment D between Hv1 and Hv2. A stop codon (TAG) was inserted between the 5' fragment M1 and T1 of the paromomycin resistance gene and between the 3' fragment M2 and T2 (however, the latter partially overlaps with M2). Hv1 and Hv2 have the same sequences as the sequence immediately before and after the start codon of Nannochloropsis PDAT1, respectively.The vectors prepared were one in which the homologous sequences Hv1 and Hv2 were both 36 bp in length (Hv1: SEQ ID NO: 5, the same sequence as the nucleotide sequence immediately before the start codon of PDAT1 / Hv2: SEQ ID NO: 7, the same sequence as the nucleotide sequence following the start codon of PDAT1) (pNICS36 vector), and one in which the homologous sequences were both 210 bp in length (Hv1: SEQ ID NO: 12, the same sequence as the nucleotide sequence immediately before the start codon of PDAT1 / Hv2: SEQ ID NO: 13, the same sequence as the nucleotide sequence following the start codon of PDAT1) (pNICS210 vector). The nucleotide sequence of the pNICS36 vector is shown in SEQ ID NO: 14, and the nucleotide sequence of the pNICS210 vector is shown in SEQ ID NO: 15.

[0188] Furthermore, as a site-specific nuclease system expression vector to be combined with the above-mentioned NICS vector (pNICS36 vector or pNICS210 vector), an all-in-one PtTALEN-ARS vector (TALEN vector_PDAT1) was prepared in which the amino acid sequence of the PtTALEN DNA binding domain in the all-in-one PtTALEN-ARS plasmid described in Non-Patent Document 3 was changed to a sequence that binds to the T3 sequence (the same sequence as the T1 and T2 sequences) around the start codon of PDAT1. A conceptual diagram showing the configuration of the prepared vector is also shown on the right side of Figure 9 (a).

[0189] Furthermore, a vector was constructed by fusing the above-mentioned NICS vector with the TALEN vector PDAT1 as an integrated vector (integrated NICS vector) shown in Figure 3. A conceptual diagram showing more specifically the structure of the constructed integrated NICS vector is shown in Figure 9(b). The integrated NICS vector shown in Figure 9 (b) has the following configuration: CEN / ARS (*), a promoter P1 (ProLHC (*)) and a terminator (terFCP (*)) for the paromomycin resistance gene, a 5'-side fragment M1 (*) and a 3'-side fragment M2 (*) of the paromomycin resistance gene between the promoter and the terminator, binding regions T1 and T2 (*) of PtTALEN for PDAT1 between M1 and M2, homologous sequences Hv1 and Hv2 (*) between T1 and T2, ProLDSP (*) as a knock-in fragment D between Hv1 and Hv2, a nucleotide sequence encoding TALEN-L containing a DNA-binding domain recognizing L1 of T1, T2, and T3 (TALEN-L, SEQ ID NO: 16), The components indicated with "*" above, including the nucleotide sequence encoding TALEN-R (TALEN-R, SEQ ID NO: 17) containing a DNA-binding domain that recognizes R1 of T1, T2, and T3, and the promoter P2 (ProLHC(*)) and terminator (terFCP(*)) for TALEN-L and TALEN-R, are common to the NICS vectors. The nucleotide sequence of the all-in-one NICS36 vector in which the homologous sequences Hv1 and Hv2 are 36 bp in length is shown in SEQ ID NO: 18, and the nucleotide sequence of the all-in-one NICS210 vector in which the homologous sequences Hv1 and Hv2 are 210 bp in length is shown in SEQ ID NO: 19. A schematic diagram showing the detailed structure of the all-in-one NICS210 vector is shown in FIG. 19. In electroporation of Nannochloropsis, it is thought that two types of vectors are simultaneously inserted into one cell in about 20% of cases (Reference I). Therefore, a higher knock-in efficiency was expected with the integrated NICS vector.

[0190] (4) Test for introducing NICS vector into cells Tests were conducted for the pNICS36 vector or pNICS210 vector alone, the combination of the pNICS36 vector or pNICS210 vector with the TALEN vector PDAT1, the all-in-one NICS36 vector, and the all-in-one NICS210 vector. Nannochloropsis cells were electroporated using 200 ng of each vector using the method described in 5-3 above, and the number of paromomycin-resistant colonies formed on F2N 50% seawater medium plates containing paromomycin was counted. The results are shown in Figure 10. As shown in Figure 10, it was confirmed that paromomycin-resistant colonies were sufficiently formed in all cells transfected with the combination of pNICS36 vector or pNICS210 vector with TALEN vector_PDAT1, the all-in-one NICS36 vector, and the all-in-one NICS210 vector. Furthermore, no colonies were formed with the pNICS36 vector or pNICS210 vector alone, confirming that background was more highly suppressed.

[0191] (5) PCR Analysis and Sequence Analysis Genomic DNA was extracted from 16 colonies randomly selected from the colonies formed in (4) above by the method described in 6-2 above, and PCR was performed by the method described in 7 above using a combination of primers designed inside the knock-in fragment (ProLDSP) and on the target DNA (upstream and downstream of PDAT1) as shown in Figure 11. The nucleotide sequences of each primer are shown in SEQ ID NOs: 26 to 29 in the order of forward primer for out-out PCR (forward primer for 5' junction PCR), reverse primer (reverse primer for 3' junction PCR), reverse primer for 5' junction PCR, and forward primer for 3' junction PCR. The amplified products after PCR for colonies formed by introducing a combination of pNICS210 vector and TALEN vector_PDAT1 were analyzed by the method described in 8 above. The results of agarose gel electrophoresis performed by the method described above in 8. are shown in FIG. 12, and the results of agarose gel electrophoresis performed by the method described above in 8. for the amplified products of the PCR reaction of the colonies formed by introducing the all-in-one NICS210 vector are shown in FIG. 13.

[0192] As shown in FIG. 11 , when the desired insertion was achieved, all of the 1601 bp, 443 bp, and 461 bp bands were confirmed. However, as shown in FIGS. 12 and 13 , when a combination of the pNICS210 vector and the TALEN vector_PDAT1 was introduced, the desired bands were confirmed in one strain (colony No. 9 in FIG. 12 ), and in five strains (colony Nos. 5, 8, 11, 13, and 14 in FIG. 13 ) when the all-in-one NICS210 vector was introduced.

[0193] Furthermore, for colonies from which the target bands were obtained as described above, each band was excised, DNA extracted, and sequence analysis was performed using the method described in 9. above to determine whether the sequence of the desired knock-in fragment ProLDSP had been introduced. Ultimately, the correct sequence was detected in 1 / 16 cases (DNA insertion efficiency: 6.25%) when a combination of pNICS210 vector and TALEN vector_PDAT1 was introduced, and in 4 / 16 cases (DNA insertion efficiency: 25%) when the all-in-one NICS210 vector was introduced, confirming that the desired insertion was possible in both cases. In particular, it was confirmed that DNA could be introduced with higher efficiency when the all-in-one NICS210 vector was introduced.

[0194] (6) CEN / ARS vector elimination test In strains in which insertion of the knock-in fragment was confirmed in (5) above, a selection vector containing CEN / ARS was formed from the NICS vector. Therefore, from some of the strains in which accurate insertion of the knock-in fragment was confirmed in (5) above (colonies No. 5 and 8 in FIG. 13), the selection vector, which is the CEN / ARS vector, was eliminated using the method described in 10. above, using paromomycin as the antibiotic. That is, after 14 days of culture in F2N liquid medium, the elimination candidate colonies (parent strains before vector elimination) obtained by plating on F2N plates were plated on F2N plates and F2N 50% seawater medium plates containing paromomycin (selection plates), respectively, and six strains were obtained that grew on F2N plates but did not grow on selection plates containing paromomycin. The plate appearance showing the growth status of each strain is shown in FIG. 14.

[0195] Next, each of the six strains obtained above and the parent strain before vector loss (colony Nos. 5 and 8 in Figure 13) were cultured in a 12-well plate in the usual way, and genomic DNA was extracted using the method in 6-2 above. Using this as a template, loss of the selected vector was confirmed by PCR (method in 7 above) using primers that detect FokI, the nuclease domain of TALEN. The amplified products after the PCR reaction were subjected to agarose gel electrophoresis using the method in 8 above, and the results are shown in Figure 15. As shown in Figure 15, FokI was not detected in any of the six strains.

[0196] Furthermore, instead of the method described in 6-2 above, highly purified genomic DNA was extracted using the method described in 6-1. This was used as a template for further detailed PCR analysis using primers for detecting the N-terminal domain of TALEN (TALEN-N), the paromomycin resistance gene (ParoR), and the kanamycin resistance gene (KanR) in addition to the above-mentioned FokI, as well as primers for out-out PCR of the knock-in fragment (donor) PDAT1 (FIG. 11). The results of agarose gel electrophoresis of the amplified products after the PCR reaction are shown in FIG. 16.

[0197] 16 , two strains each from colony No. 5 and colony No. 8 were obtained with a high probability, in which the PDAT1 band was confirmed and no bands for any of the genes derived from the selection vector (FokI, TALEN-N, ParoR, KanR) were confirmed (strains derived from colony No. 5: #1, #2, strains derived from colony No. 8: #4, #5). These results confirmed that the method using the NICS vector of the present invention allows for the accurate insertion of a desired nucleotide sequence (in this test example, the LDSP promoter) into the target site of the target DNA (upstream of PDAT1 in this test example), and further allows for the construction of a genomic DNA-edited strain in which the vector is subsequently dropped and foreign genes other than the desired nucleotide sequence are removed.

[0198] Test Example 3: Verification of DNA editing targeting GPAT1 It was confirmed that DNA can be introduced into different target sites using the NICS vector of the present invention. In this test example, the upstream site of GPAT1 (glycerol-3-phosphate acyltransferase) in Nannochloropsis was selected as the target site.

[0199] (1) Construction of NICS Vector (Example) First, in the same manner as in the all-in-one NICS210 vector of Test Example 2(3), the following configuration was constructed: CEN / ARS(*), promoter P1 (ProLHC(*)) and terminator (terFCP(*)) for the paromomycin resistance gene, 5'-end fragment M1(*) and 3'-end fragment M2(*) of the paromomycin resistance gene between the promoter and the terminator, binding regions T1 and T2 of PtTALEN for GPAT1 between M1 and M2 (both SEQ ID NO: 30, 5'-L1 (Left-TALEN DNA binding domain recognition sequence, SEQ ID NO: 31)-S1 (spacer sequence)-R1 (complementary sequence of the Right-TALEN DNA binding domain recognition sequence, SEQ ID NO: 32)-3'), The homologous sequences Hv1 and Hv2 are located between T1 and T2, ProLDSP(*) is located between Hv1 and Hv2 as knock-in fragment D, a nucleotide sequence encoding TALEN-L (TALEN-L, SEQ ID NO: 35) containing a DNA-binding domain that recognizes L1 of T1, T2, and T3, a nucleotide sequence encoding TALEN-R (TALEN-R, SEQ ID NO: 36) containing a DNA-binding domain that recognizes R1 of T1, T2, and T3, and a promoter P2 (ProLHC(*)) and terminator (terFCP(*)) for TALEN-L and TALEN-R. The structures indicated by "*" above are common to the NICS vector and integrated NICS vector, respectively. Furthermore, T1 and T2 each have the same sequence as T3, a sequence around the start codon of Nannochloropsis GPAT1. The lengths of the homologous sequences Hv1 and Hv2 were 200 bp (Hv1; SEQ ID NO: 33, the same sequence as the nucleotide sequence immediately before the start codon of GPAT1) and 208 bp (Hv2; SEQ ID NO: 34, the same sequence as the nucleotide sequence after the start codon of GPAT1), respectively (all-in-one NICS210-GPAT1 vector). The nucleotide sequence of the all-in-one NICS210-GPAT1 vector is shown in SEQ ID NO: 37.

[0200] (2) NICS Vector Cell Introduction Test A cell introduction test was performed in the same manner as in Test Example 2(4), except that the all-in-one NICS210-GPAT1 vector was used instead of the all-in-one NICS210 vector. Genomic DNA was extracted from 12 randomly selected colonies from the colonies formed on a paromomycin-containing F2N 50% seawater medium plate in the same manner as in Test Example 2(5), using the method described in 6-2 above, and PCR reactions were performed. The results of agarose gel electrophoresis of the amplified products after the PCR reaction are shown in Figure 20. In Figure 20, the position of the band observed when the desired insertion (knock-in) was achieved is indicated by a filled triangle, and the position of the band observed when no insertion occurred (WT) is indicated by a filled triangle.

[0201] As shown in Figure 20, as a result of introduction of the all-in-one NICS210-GPAT1 vector, the desired band was confirmed in five strains (colony Nos. 1 to 4 and 7 in Figure 20). Furthermore, the colonies from which the desired band was obtained were sequenced in the same manner as in Test Example 2(5). Ultimately, even when the all-in-one NICS210-GPAT1 vector was introduced, the correct sequence was detected in 2 / 12 strains (DNA insertion efficiency: 17%), confirming that DNA can be introduced with high efficiency into the target site, i.e., the upstream site of GPAT1.

[0202] (3) CEN / ARS vector elimination test From some of the strains in which accurate insertion of the knock-in fragment was confirmed in (2) above (colonies No. 3 and 4 in FIG. 20), the selection vector, which is a CEN / ARS vector, was removed in the same manner as in Test Example 2 (6), using paromomycin as the antibiotic. As a result, colonies that grew on the F2N plate but did not grow on the selection plate containing paromomycin were obtained. Six colonies (#3, #4, #6-9) from colony No. 3 and six colonies (#1-4, #6, #7) from colony No. 4. It was confirmed that in this test example, the CEN / ARS vector was removed and a genomic DNA-edited strain in which foreign genes other than the desired nucleotide sequence were removed could be constructed. The plate appearance showing the growth status of each strain is shown in FIG. 21.

[0203] Test Example 4 Verification of the length of homologous sequences in integrated NICS vectors (1) Construction of NICS vector (Example) An integrated NICS vector (all-in-one NICS400 vector) was constructed in the same manner as the all-in-one NICS210 vector in Test Example 2(3), except that the lengths of the homologous sequences Hv1 and Hv2 in the integrated NICS vector were both 414 bp (Hv1; SEQ ID NO: 38, the same sequence as the nucleotide sequence immediately before the start codon of PDAT1 / Hv2; SEQ ID NO: 39, the same sequence as the nucleotide sequence after the start codon of PDAT1). The nucleotide sequence of the all-in-one NICS400 vector is shown in SEQ ID NO: 40.

[0204] (2) NICS Vector Cell Introduction Test A cell introduction test was performed in the same manner as in Test Example 2(4), except that the all-in-one NICS400 vector was used instead of the all-in-one NICS210 vector. Genomic DNA was extracted from 12 randomly selected colonies formed on a paromomycin-containing F2N 50% seawater medium plate in the same manner as in Test Example 2(5), using the method described in 6-2 above, and PCR reactions were performed. The results of agarose gel electrophoresis of the amplified products after PCR are shown in Figure 22. In Figure 22, the position of the band observed when the desired insertion was achieved is indicated by a filled triangle, and the position of the band observed when no insertion occurred (WT) is indicated by a filled triangle.

[0205] As shown in Figure 22, as a result of introduction of the all-in-one NICS400 vector, the desired band was confirmed in three strains (colony Nos. 4, 6, and 9 in Figure 22). Furthermore, the colonies from which the desired band was obtained were sequenced in the same manner as in Test Example 2(5). Ultimately, even when the all-in-one NICS400 vector was introduced, the correct sequence was detected in 3 / 12 (DNA insertion efficiency: 25%), confirming that DNA can be introduced with high efficiency.

[0206] Test Example 5: Application of the NICS System to Cultured Human Cells As an alternative to the method shown in Figure 1A, the method shown in Figure 23 was designed, and it was confirmed that the vector of the present invention can also be applied to cultured human cells. In the method shown in Figure 23, a selectable marker gene (in this test example, a puromycin resistance gene) was divided into a 5' end (M1) and a 3' end (M2) and a vector was constructed in which sequences homologous to the nucleotide sequences at both ends of the target site (Hv1, Hv2) and the target DNA (D, in this test example, a 3x Flag tag sequence) were inserted between the 5' end and the target DNA (D) as knock-in fragments that could be removed by a site-specific nuclease system (in this test example, a CRISPR-Cas system) (top panel of Figure 23). This vector was cleaved in cells into which the site-specific nuclease system had been introduced, i.e., cells in which the target DNA was likely also cleaved and the knock-in fragment was inserted (bottom right panel of Figure 23), and the remaining fragments were bound, allowing the selectable marker gene to function (bottom left panel of Figure 23). In this test example, downstream sites of PARP1 and ATP5B among genes (endogenous genes) on the human genome were selected as target sites.

[0207] (1) Construction of NICS vector (Example) A vector (NICS vector) used in the method shown in Fig. 1A was constructed in the same manner as in (3) of Test Example 2. A conceptual diagram showing more specifically the structure of the vector constructed as the NICS vector shown in Fig. 1A(a) and Fig. 1C(b) is shown in the upper part of Fig. 23. The NICS vector shown in Figure 23 has the following configuration: promoter P1 (pCMV, SEQ ID NO: 41) and polyA (bGH polyA signal, SEQ ID NO: 42) for the puromycin resistance gene, and a sequence in which the puromycin resistance gene (PuroR) is divided into a 5'-side fragment M1 (PuroR-5', SEQ ID NO: 43) and a 3'-side fragment M2 (PuroR-3', SEQ ID NO: 44) with a 60-bp overlap sequence between the promoter and polyA, or a sequence in which the puromycin resistance gene (PuroR) is divided into a 5'-side fragment M1 (PuroR-5', SEQ ID NO: 51 (same as SEQ ID NO: 43)) and a 3'-side fragment M2 (PuroR-3', SEQ ID NO: 52) with a 192-bp overlap sequence, Between M1 and M2, gRNA recognition sequence G1 (SEQ ID NO: 45, common to both PARP1 and ATP5B) and gRNA recognition sequence G2 (complementary sequence of G1, SEQ ID NO: 46, common to both PARP1 and ATP5B), homologous sequences Hv1 and Hv2 between G1 and G2, and a sequence encoding a 3xFlag tag (SEQ ID NO: 47) as knock-in fragment D between Hv1 and Hv2, and a stop codon (TAG or TAA) was inserted between the 5' fragments M1 and G1 of the puromycin resistance gene and between the 3' fragments M2 and G2. Hv1 and Hv2 have the same sequences as the sequence immediately before the stop codon and the sequence following the stop codon of PARP1 and ATP5B, respectively. The vector had homologous sequences Hv1 and Hv2 each 40 bp long ([PARP1] Hv1: SEQ ID NO: 48, the same sequence as the nucleotide sequence immediately preceding the stop codon of PARP1 / Hv2: SEQ ID NO: 49, the same sequence as the nucleotide sequence following the stop codon of PARP1; [ATP5B] Hv1: SEQ ID NO: 54, the same sequence as the nucleotide sequence immediately preceding the stop codon of ATP5B / Hv2: SEQ ID NO: 55, the same sequence as the nucleotide sequence following the stop codon of ATP5B).The nucleotide sequence of the NICS vector for PARP1 (pNICS60-PARP1 vector) in which the overlapping sequence of the marker gene is 60 bp is shown in SEQ ID NO: 50, the nucleotide sequence of the NICS vector for PARP1 (pNICS192-PARP1 vector) in which the overlapping sequence of the marker gene is 192 bp is shown in SEQ ID NO: 53, the nucleotide sequence of the NICS vector for ATP5B (pNICS60-ATP5B vector) in which the overlapping sequence of the marker gene is 60 bp is shown in SEQ ID NO: 56, and the nucleotide sequence of the NICS vector for ATP5B (pNICS192-ATP5B vector) in which the overlapping sequence of the marker gene is 192 bp is shown in SEQ ID NO: 57.

[0208] Furthermore, as a site-specific nuclease system expression vector to be combined with the NICS vector, a CRISPR / Cas9 vector was prepared in which the guide RNA (gRNA) sequences in the CRISPR-Cas9 vector described in Sakura et al., NATURE PROTOCOLS, Vol. 11, No. 1, 2016, pp. 118-133 were changed to sequences that bind to G1, G2, and G3 (common to G1 to G3, sequences around the stop codon of PARP1 or ATP5B).

[0209] (2) Verification Test It was confirmed that cells transfected with vectors other than the expression vector for undivided PuroR did not exhibit puromycin resistance. Specifically, no vector (untransfected), pTA2-PuroR (a vector containing undivided PuroR, positive control), CRISPR / Cas9 vector (negative control), and pTA2-PuroR-Mut-T162A vector (a vector inactivated by introducing a mutation into PuroR) were each transfected into HEK293T cells by the method described in 12-3 above. The cells were then cultured and harvested at a puromycin concentration of 0 μg / mL (-) or 20 μg / mL (+) by the method described in 12-4 above. The cell number was counted by the method described in 12-5 above, and viability was calculated. The results are shown in Figure 24.

[0210] As shown in Figure 24, except for the positive control, most of the cells died due to puromycin treatment, and the cell viability decreased to less than 20%, confirming that the cells did not grow in the presence of puromycin.

[0211] (3) Test for introducing NICS vector into cells The test was performed using no vector (Untransfected: WT), NICS vector only (pNICS60-PARP1 vector, pNICS192-PARP1 vector, pNICS60-ATP5B vector, or pNICS192-ATP5B vector), and a combination of a guide RNA recognition sequence (G3) on the gene targeted by each NICS vector and a CRISPR / Cas9 vector encoding a corresponding gRNA (i.e., a CRISPR / Cas9 vector targeting the gene).

[0212] These were each introduced into HEK293T in the same manner as in (2) above, and viability was calculated at a puromycin concentration of 0 μg / mL (-) or 20 μg / mL (+). As for the results for PARP1, for each combination of NICS vector (pNICS60-PARP1 vector, pNICS192-PARP1 vector) and CRISPR / Cas9 vector targeting PARP1, the survival rate under each puromycin concentration is shown in Figure 25, and as for the results for ATP5B, for each combination of NICS vector (pNICS192-ATP5B vector) and CRISPR / Cas9 vector targeting ATP5B, the survival rate under each puromycin concentration is shown in Figure 26.

[0213] As shown in Figures 25 and 26, in cells transfected with only the NICS vector, the survival rate at a puromycin concentration of 20 μg / mL was less than 20%, and most of the cells died, but all cells co-transfected with the CRISPR / Cas9 vector showed high survival rates. This confirmed that the NICS vector from which the 3xFlag tag sequence was excised by the CRISPR / Cas9 vector recombined via the overlapping sequence, resulting in the expression of the puromycin resistance gene (PuroR) (Figure 23, bottom left).

[0214] (4) PCR Analysis For the combination of no vector (untransfected: WT) and each NICS vector and CRISPR / Cas9 vector, after (3) above, an out-out PCR reaction was performed using the methods described in 13-1. to 13-2. above (n = 4 each). The results of agarose gel electrophoresis of the amplified products after the PCR reaction using the method described in 8. above are shown in Figures 27A and 27B (PARP1), and Figures 28A and 28B (ATP5B), respectively. When the desired insertion is achieved, the confirmed band length will be 349 bp (before insertion) to 425 bp (after insertion) for PARP1, and 347 bp (before insertion) to 424 bp (after insertion) for ATP5B.

[0215] As shown in Figures 27A to 28B, each NICS vector and CRISPR / Cas9 vector were co-introduced, and the expected band lengths after insertion were confirmed in colonies formed at a puromycin concentration of 20 μg / mL (+).

[0216] (5) TIDER Analysis From the PCR product of (4) above, TIDER analysis was performed using the methods described in 14-1 to 14-3 above, and HDR efficiency (HDR efficiency [%], n = 4) was determined. As a result, it was confirmed that insertion of the 3x Flag tag sequence occurred under all conditions. As an example of a comparison of HDR efficiency (insertion efficiency) with or without puromycin selection, the results when the pNICS192-PARP1 vector and the CRISPR / Cas9 vector were introduced in combination (Figure 27B) are shown in Figure 29. As shown in Figure 29, it was confirmed that in this combination, the addition of an antibiotic (puromycin) corresponding to the marker gene significantly increased insertion efficiency.

[0217] From the above, it has been confirmed that the NICS system of the present invention can obtain DNA-edited cells (e.g., genome-edited cells) in which target DNA has been edited, whether from algae or cells derived from a different biological species (e.g., humans), and that the obtained DNA-edited cells can be easily selected and isolated by appropriately selecting, without being limited to, the target gene locus or marker gene according to the purpose.

[0218] As described above, according to the present invention, it is possible to provide a DNA editing method that can accurately and efficiently insert a desired nucleotide sequence into a target site of target DNA in a cell using a vector or remove the target site, a cell production method using the same, and a DNA editing vector and a DNA editing kit for use in these methods.

[0219] Furthermore, when the vector contains the autonomously replicating sequence CEN / ARS, it is further possible to provide a DNA editing method that can insert a desired nucleotide sequence into a target site of a target DNA using the vector or remove the target site from the target DNA, and then drop the vector to highly efficiently obtain genomic DNA-edited cells in which foreign genes other than the inserted nucleotide sequence have been removed, a cell production method using the same, and a DNA editing vector and a DNA editing kit for use in these methods.

[0220] For example, by setting the target site immediately before the start codon of the target gene, and inserting only a strong endogenous promoter (e.g., the above-mentioned ProLDSP) into this site, and removing the rest of the vector, it becomes possible to overexpress the target gene.

Claims

1. A method for editing DNA for inserting a desired nucleotide sequence into a target site of a target DNA in a cell or removing the target site, comprising an introduction step of introducing a vector and a site-specific nuclease system into a cell and contacting the target DNA, wherein the vector comprises a first promoter P1, and the following structure (1): 5'-M1-Hv1-D-Hv2-M2-3' ... (1) [In (1), M1 represents a 5' fragment of a nucleotide sequence encoding a selection marker gene and is operably linked to a first promoter P1, Hv1 represents a nucleotide sequence homologous to a first nucleotide sequence Ht1 on the 5' side of the target site of the target DNA, D represents the desired nucleotide sequence but is optional, Hv2 represents a nucleotide sequence homologous to a second nucleotide sequence Ht2 on the 3' side of the target site of the target DNA, M2 represents the remaining 3' fragment of the nucleotide sequence encoding the selection marker gene, and adjacent sequences in M1, Hv1, D, Hv2, and M2 may partially overlap each other. a cleavage step of generating a fragment represented by the following structure (2): 5'-Hv1-D-Hv2-3' ... (2) and a fragment represented by the following structure (3): 5'-M2-P1-M1-3' ... (3) from the vector by the site-specific nuclease system, and cleaving the target site or its vicinity in the target DNA; an editing step of binding between the target DNA and the fragment represented by structure (2) depending on the homology between Ht1 and Hv1, and binding depending on the homology between Ht2 and Hv2, thereby inserting a desired nucleotide sequence D into the target site or removing the target site; and a selection step of obtaining a selection vector in which the 3' end of M1 and the 5' end of M2 in the fragment represented by structure (3) are bound to each other to operably link to P1 and contain a functional selection marker gene.

2. The DNA editing method of claim 1, wherein the vector further comprises an autonomously replicating sequence CEN / ARS, the structure (3) produced in the cleavage step further comprises CEN / ARS, and the selection step is a step of obtaining a selection vector in which the 3' end of M1 and the 5' end of M2 in the fragment represented by structure (3) are bound to each other to be operably linked to P1 and which comprises a functional selection marker gene and CEN / ARS.

3. The method for editing DNA according to claim 1, wherein the length of Hv1 and the length of Hv2 are each independently 30 to 600 bases.

4. The vector has the following structure (11) as the structure (1): 5'-M1-T1-Hv1-D-Hv2-T2-M2-3' ... (11) [In (11), T1 represents a TALEN_1 binding region comprising a first DNA-binding domain recognition sequence or its complementary sequence L1, and a second DNA-binding domain recognition sequence or its complementary sequence R1, T2 represents a TALEN_2 binding region comprising a third DNA-binding domain recognition sequence or its complementary sequence L2, and a fourth DNA-binding domain recognition sequence or its complementary sequence R2, M1, Hv1, D, Hv2, and M2 are each defined as in the structure (1), and adjacent sequences in M1, T1, Hv1, D, Hv2, T2, and M2 may partially overlap each other. ]; and the site-specific nuclease system comprises a TALEN comprising a DNA-binding domain and a nuclease domain, wherein the TALEN comprises a first DNA-binding domain and a second DNA-binding domain, and generates a 5'-end of structure (2); a TALEN comprises a third DNA-binding domain and a fourth DNA-binding domain, and generates a 3'-end of structure (2); and a TALEN comprises a fifth DNA-binding domain that recognizes a nucleotide sequence on the 5' side of a region T3 including a target site of the target DNA as a fifth DNA-binding domain recognition sequence or its complementary sequence L3, and a sixth DNA-binding domain that recognizes a nucleotide sequence on the 3' side of the region T3 as a sixth DNA-binding domain recognition sequence or its complementary sequence R3, and cleaves the target site or a vicinity thereof in the target DNA.

5. The vector includes a first guide RNA recognition sequence or its complementary sequence G1 and a second guide RNA recognition sequence or its complementary sequence G2 in a structure (1), and G1 may be between M1 and Hv1 and overlap with at least one of M1 and Hv1, and G2 may be between M2 and Hv2 and overlap with at least one of M2 and Hv2; the site-specific nuclease system is a CRISPR-Cas system including a Cas protein and its guide RNA, CRISPR-Cas system_1 including a first guide RNA and the Cas protein generating the 5' end of the structure (2); and CRISPR-Cas system_2 including a second guide RNA and the Cas protein generating the 3' end of the structure (2); The DNA editing method according to claim 1, comprising: a third guide RNA that recognizes a nucleotide sequence present so as to include a target site in the target DNA as a third guide RNA recognition sequence or its complementary sequence G3; and a CRISPR-Cas system_3 in which a Cas protein cleaves the target site or its vicinity in the target DNA.

6. The DNA editing method of claim 1, wherein the introduction of the site-specific nuclease system into a cell is the introduction of a nuclease system expression vector comprising an autonomously replicating sequence CEN / ARS, a second promoter P2, and a nucleotide sequence Nuc encoding the site-specific nuclease system operably linked to the second promoter P2.

7. The DNA editing method of claim 1, wherein the introduction of the vector and site-specific nuclease system into a cell is the introduction of an integrated vector comprising: a first promoter P1; structure (1); a second promoter P2; and a nucleotide sequence Nuc encoding the site-specific nuclease system operably linked to the second promoter P2; the structure (3) produced in the cleavage step further comprises P2 and Nuc operably linked to P2; and the selection step is a step in which the 3' end of M1 and the 5' end of M2 in the fragment represented by structure (3) are bound to obtain a selection vector that is operably linked to P1 and contains a functional selection marker gene and Nuc operably linked to P2.

8. The DNA editing method of claim 7, wherein the integrated vector further comprises an autonomously replicating sequence CEN / ARS, the structure (3) produced in the cleavage step further comprises CEN / ARS, and the selection step is a step of obtaining a selection vector in which the 3' end of M1 and the 5' end of M2 in the fragment represented by structure (3) are bound to be operably linked to P1 and which comprises a functional selection marker gene, CEN / ARS, and Nuc operably linked to P2.

9. A DNA editing method described in any one of claims 6 to 8, wherein the nucleotide sequence Nuc encoding the site-specific nuclease system is a nucleotide sequence encoding a fusion protein of a DNA binding domain and a nuclease domain.

10. A DNA editing method described in any one of claims 6 to 8, wherein the nucleotide sequence Nuc encoding the site-specific nuclease system is a nucleotide sequence encoding a Cas protein and a nucleotide sequence encoding its guide RNA.

11. A method for producing DNA-edited cells in which a desired nucleotide sequence has been inserted into a target site of a target DNA or in which the target site has been removed, comprising: a step of obtaining cells in which the desired nucleotide sequence D has been inserted into the target site or the target site has been removed by a DNA editing method described in any one of claims 1 to 8 and which contain the selection vector; and a step of selecting DNA-edited cells in which the desired nucleotide sequence D has been inserted into the target site or the target site has been removed, using the selection marker gene contained in the selection vector as an indicator.

12. The cell manufacturing method described in claim 11, wherein the vector further comprises an autonomously replicating sequence CEN / ARS, and further comprises a step of culturing the DNA-edited cells to remove the selection vector from the cells.

13. A vector for inserting a desired nucleotide sequence into a target site of a target DNA or for removing the target site by a site-specific nuclease system, comprising a first promoter P1, and the following structure (1'): 5'-M1-Hv1'-D'-Hv2'-M2-3' ... (1') [In (1'), M1 represents a 5' fragment of a nucleotide sequence encoding a selection marker gene and is operably linked to a first promoter P1; Hv1' represents a nucleotide sequence homologous to a first nucleotide sequence Ht1 on the 5' side of the target site of the target DNA or an insertion site thereof; D' represents the desired nucleotide sequence or an insertion site thereof, but may be absent; Hv2' represents a nucleotide sequence homologous to a second nucleotide sequence Ht2 on the 3' side of the target site of the target DNA or an insertion site thereof; M2 represents the remaining 3' fragment of the nucleotide sequence encoding the selection marker gene; and adjacent sequences in M1, Hv1', D', Hv2', and M2 may partially overlap with each other. and a fragment having the following structure (2'): 5'-Hv1'-D'-Hv2'-3'...(2') and a fragment having the following structure (3'): 5'-M2-P1-M1-3'...(3') are generated by the site-specific nuclease system.

14. The DNA editing vector of claim 13, further comprising an autonomously replicating sequence CEN / ARS, wherein the site-specific nuclease system generates a fragment further comprising CEN / ARS as structure (3').

15. The following structure (11') may be used as the structure (1'): 5'-M1-T1'-Hv1'-D'-Hv2'-T2'-M2-3' ... (11') [In (11'), T1' represents a TALEN_1 binding region or an insertion site thereof, which comprises a first DNA-binding domain recognition sequence or its complementary sequence L1, and a second DNA-binding domain recognition sequence or its complementary sequence R1; T2' represents a TALEN_2 binding region or an insertion site thereof, which comprises a third DNA-binding domain recognition sequence or its complementary sequence L2, and a fourth DNA-binding domain recognition sequence or its complementary sequence R2; M1, Hv1', D', Hv2', and M2 are each as defined in the structure (1'); and in M1, T1', Hv1', D', Hv2', T2', and M2, adjacent sequences may partially overlap with each other.

14. The DNA editing vector of claim 13, wherein the site-specific nuclease system comprises a TALEN comprising a DNA-binding domain and a nuclease domain: TALEN_1 comprising a first DNA-binding domain and a second DNA-binding domain, and generating a 5'-end of structure (2'); TALEN_2 comprising a third DNA-binding domain and a fourth DNA-binding domain, and generating a 3'-end of structure (2'); and TALEN_3 comprising a fifth DNA-binding domain that recognizes a nucleotide sequence on the 5' side of a region T3 including a target site of the target DNA as a fifth DNA-binding domain recognition sequence or its complementary sequence L3, and a sixth DNA-binding domain that recognizes a nucleotide sequence on the 3' side as a sixth DNA-binding domain recognition sequence or its complementary sequence R3, and cleaves the target site or its vicinity in the target DNA.

16. A structure (1') includes a first guide RNA recognition sequence or its complementary sequence or its insertion site G1', and a second guide RNA recognition sequence or its complementary sequence or its insertion site G2', and G1' is between M1 and Hv1' and may overlap with at least one of M1 and Hv1', and G2' is between M2 and Hv2' and may overlap with at least one of M2 and Hv2', and the site-specific nuclease system is a CRISPR-Cas system including a Cas protein and its guide RNA, CRISPR-Cas system_1 including a first guide RNA and the Cas protein generating the 5' end of structure (2'), and CRISPR-Cas system_2 including a second guide RNA and the Cas protein generating the 3' end of structure (2'), The DNA editing vector according to claim 13, comprising: a third guide RNA that recognizes a nucleotide sequence present so as to include a target site in the target DNA as a third guide RNA recognition sequence or its complementary sequence G3; and a CRISPR-Cas system_3 in which a Cas protein cleaves the target site or its surroundings in the target DNA.

17. The DNA editing vector of claim 13, which is an integrated vector comprising a first promoter P1, a structure (1'), a second promoter P2, and a nucleotide sequence Nuc encoding the site-specific nuclease system operably linked to the second promoter P2, and the site-specific nuclease system generates a fragment further comprising P2 and Nuc operably linked to P2 as structure (3').

18. The DNA editing vector of claim 17, further comprising an autonomously replicating sequence CEN / ARS, wherein the site-specific nuclease system generates a fragment further comprising CEN / ARS as structure (3').

19. The DNA editing vector described in claim 13, wherein M1 and M2 are nucleotide sequences in which the selection marker gene is interrupted so that the 3' end of M1 and the 5' end of M2 of the fragment represented by the structure (3') can be linked and function.

20. The DNA editing vector described in claim 19, wherein the 3' end of M1 and the 5' end of M2 are nucleotide sequences that overlap with each other, and the selection marker gene functions by binding the 3' end of M1 and the 5' end of M2 via the overlapping nucleotide sequence.

21. The DNA editing vector according to claim 20, wherein the overlapping nucleotide sequences are 40 to 500 bases in length.

22. The DNA editing vector of claim 21, wherein a stop codon is added to the 3' end of M1 and / or the 5' end of M2, and the stop codon is removed from M1 and / or M2 by binding via the overlapping nucleotide sequences.

23. A DNA editing kit comprising the DNA editing vector described in any one of claims 13 to 22 and the site-specific nuclease system.

24. The DNA editing kit of claim 23, wherein the site-specific nuclease system is a nuclease system expression vector comprising an autonomously replicating sequence CEN / ARS, a second promoter P2, and a nucleotide sequence Nuc encoding the site-specific nuclease system operably linked to the second promoter P2.

Citation Information

Patent Citations

  • Vector for nucleic acid insertion

    WO2015068785A1